{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:ChenEddy Sept2016.jpg|frameless|upright=0.3|center]]
|<big>[[User:Eddychen|Eddy J. Chen, MD]]<br>Boston, MA</big>
|-
|}
''Are you looking for a regimen, but can't find it here? It is possible that we've moved it to the [[Prostate_cancer_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!'' 
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}

{{TOC limit|limit=3}}

=Guidelines=
==[https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/genitourinary-cancer ASCO]==
*'''2018:''' Morris et al. [http://ascopubs.org/doi/full/10.1200/JCO.2018.78.0619 Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline]
*'''2017:''' Virgo et al. [http://ascopubs.org/doi/full/10.1200/JCO.2017.72.8030 Second-Line Hormonal Therapy for Men With Chemotherapy-Na√Øve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion] [https://www.ncbi.nlm.nih.gov/pubmed/28441112 PubMed]
*'''2016:''' [https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/genitourinary-cancer#/9336 Active Surveillance for the Management of Localized Prostate Cancer Endorsement]
*'''2015:''' [https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/genitourinary-cancer#/9426 Prostate Cancer Survivorship Care Guideline Endorsement]
===Older===
*'''2014:''' [https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/genitourinary-cancer#/9486 Adjuvant and Salvage Radiotherapy After Prostatectomy Endorsement]
*'''2012:''' [https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/genitourinary-cancer#/9501 Screening for Prostate Cancer with Prostate-Specific Antigen (PSA) Testing PCO]
*'''2009:''' [https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/genitourinary-cancer#/9511 Use of 5-alpha Reductase Inhibitors for Prostate Cancer Chemoprevention]
*'''2007:''' [https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/genitourinary-cancer#/9516 Non-Hormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer Endorsement]

==ASCO & CCO==
*'''2014:''' Basch et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876355/ Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline]

==AUA==
*[https://www.auanet.org/education/guidelines/castration-resistant-prostate-cancer.cfm Castration-Resistant Prostate Cancer: AUA Guideline @ AUAnet] 
**[https://www.auanet.org/common/pdf/education/clinical-guidance/Castration-Resistant-Prostate-Cancer.pdf PDF (2015) @ AUAnet]
*[http://www.jurology.com/article/S0022-5347(15)05026-0/abstract Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015] [https://www.ncbi.nlm.nih.gov/pubmed/26498056 PubMed] 

==EAU/ESTRO/SIOG==
*'''2017:''' [http://www.europeanurology.com/article/S0302-2838(16)30469-9/fulltext EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer] [https://www.ncbi.nlm.nih.gov/pubmed/27591931 PubMed]

==[http://www.esmo.org/ ESMO]==
*'''2015:''' Parker et al. [https://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]

===Older===
*'''2013:''' Horwich et al. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt208 ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/23813930 PubMed]
*'''2012:''' Horwich et al. [https://annonc.oxfordjournals.org/content/24/5/1141.full.pdf+html ESMO Consensus Conference Guidelines] [https://www.ncbi.nlm.nih.gov/pubmed/23303340 PubMed]

==[https://www.nccn.org/ NCCN]==
*[http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf NCCN Guidelines - Prostate Cancer]

==St Gallen==
*'''2015:''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511225/ Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC)]

=Induction ADT=
==ADT {{#subobject:8ab01b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ADT: '''<u>A</u>'''ndrogen '''<u>D</u>'''eprivation '''<u>T</u>'''herapy
===Regimen {{#subobject:25b39f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.05.004 Roach et al. 2003 (RTOG 94-13)]
|style="background-color:#1a9851"|Phase III (E)
|Adjuvant ADT
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.58.0662 Pisansky et al. 2014 (RTOG 9910)]
|style="background-color:#1a9851"|Phase III (C)
|ADT x 28 weeks
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: these are clinical trials that did not specify a particular drug to be used for androgen deprivation. See papers for details.''
====Hormonotherapy====
*[[:Category:GnRH agonists|LHRH agonist]]
*[[Bicalutamide (Casodex)]] or [[Flutamide (Eulexin)]]

'''8-week course'''
====Subsequent treatment====
*[[#ADT_.26_RT|ADT & RT]]
===References===
# '''RTOG 94-13:''' Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS; Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003 May 15;21(10):1904-11. [http://ascopubs.org/doi/full/10.1200/JCO.2003.05.004 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12743142 PubMed]
## '''Update:''' Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR Jr. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55. Epub 2007 May 24. [https://www.redjournal.org/article/S0360-3016(07)00641-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917177/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/17531401 PubMed]
# '''RTOG 9910:''' Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 1;33(4):332-9. Epub 2014 Dec 22. [http://ascopubs.org/doi/full/10.1200/JCO.2014.58.0662 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302214/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25534388 PubMed]

==Flutamide & Goserelin {{#subobject:b10d66 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:afbb9c |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.redjournal.org/article/S0360-3016(04)00264-0/fulltext Crook et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|Flutamide & Goserelin x 8 mo
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Hormonotherapy====
*[[Flutamide (Eulexin)]]
*[[Goserelin (Zoladex)]]

'''3-month course'''
====Subsequent treatment====
*[[Prostate_cancer_-_historical#Radiation_therapy|RT]]
===References===
# Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G. Report of a multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):15-23. [https://www.redjournal.org/article/S0360-3016(04)00264-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15337535 PubMed]

=Definitive therapy, including active surveillance=
==Active surveillance==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa012794 Holmberg et al. 2002 (SPCG-4)]
| style="background-color:#1a9851" |Phase III (C)
|[[Surgery#Radical_prostatectomy|Radical prostatectomy]]
| style="background-color:#d73027" |Inferior OS (*)
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61619-X/fulltext Fleshner et al. 2012 (REDEEM)]
| style="background-color:#1a9851" |Phase III (C)
|Dutasteride
| style="background-color:#d73027" |Inferior TTP
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429335/ Wilt et al. 2012 (PIVOT)]
| style="background-color:#1a9851" |Phase III (C)
|[[Surgery#Radical_prostatectomy|Radical prostatectomy]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30661-1/fulltext Azzouzi et al. 2016 (CLIN1001 PCM301)]
| style="background-color:#1a9851" |Phase III (C)
|Padeliporfin
| style="background-color:#d73027" |Inferior TTP
|-
|}
''No antineoplastic therapy; consists of various strategies of close monitoring and re-biopsy. Efficacy for SPCG-4 is based on the 2014 update.''
===References===
# '''SPCG-4:''' Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, H√§ggman M, Andersson SO, Sp√•ngberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norl√©n BJ; Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002 Sep 12;347(11):781-9. [https://www.nejm.org/doi/10.1056/NEJMoa012794 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12226148 PubMed]
## '''Update:''' Bill-Axelson A, Holmberg L, Ruutu M, H√§ggman M, Andersson SO, Bratell S, Sp√•ngberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norl√©n BJ, Johansson JE; Scandinavian Prostate Cancer Group Study No 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005 May 12;352(19):1977-84. [https://www.nejm.org/doi/full/10.1056/NEJMoa043739 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15888698 PubMed]
## '''Update:''' Bill-Axelson A, Holmberg L, Fil√©n F, Ruutu M, Garmo H, Busch C, Nordling S, H√§ggman M, Andersson SO, Bratell S, Sp√•ngberg A, Palmgren J, Adami HO, Johansson JE; Scandinavian Prostate Cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54. Epub 2008 Aug 11. [https://academic.oup.com/jnci/article/100/16/1144/916419 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518167/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18695132 PubMed]
## '''Update:''' Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, H√§ggman M, Andersson SO, Bratell S, Sp√•ngberg A, Palmgren J, Steineck G, Adami HO, Johansson JE; SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011 May 5;364(18):1708-17. [https://www.nejm.org/doi/10.1056/NEJMoa1011967 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21542742 PubMed]
## '''Update:''' Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, Nordling S, H√§ggman M, Andersson SO, Sp√•ngberg A, Andr√©n O, Palmgren J, Steineck G, Adami HO, Johansson JE. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014 Mar 6;370(10):932-42. [https://www.nejm.org/doi/10.1056/NEJMoa1311593 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118145/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24597866 PubMed]
## '''Update:''' Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, H√§ggman M, Andersson SO, Andr√©n O, Steineck G, Adami HO, Johansson JE. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med. 2018 Dec 13;379(24):2319-2329. [https://www.nejm.org/doi/full/10.1056/NEJMoa1807801 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30575473 PubMed]
# '''REDEEM:''' Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012 Mar 24;379(9821):1103-11. Epub 2012 Jan 24. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61619-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22277570 PubMed]
# '''PIVOT:''' Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012 Jul 19;367(3):203-13. Erratum in: N Engl J Med. 2012 Aug 9;367(6):582. [https://www.nejm.org/doi/10.1056/NEJMoa1113162 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429335/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22808955 PubMed]
## '''Update:''' Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, Aronson WJ, Brawer MK. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017 Jul 13;377(2):132-142. [https://www.nejm.org/doi/10.1056/NEJMoa1615869 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28700844 PubMed]
# '''CLIN1001 PCM301:''' Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M; PCM301 Study Group. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017 Feb;18(2):181-191. Epub 2016 Dec 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30661-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28007457 PubMed]

==ADT {{#subobject:c3c2cb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ADT: '''<u>A</u>'''ndrogen '''<u>D</u>'''eprivation '''<u>T</u>'''herapy
===Regimen {{#subobject:c615a3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243932/ Warde et al. 2011 (NCIC CTG PR.3/UK MRC PR07)]
| style="background-color:#1a9851" |Phase III (C)
|[[#ADT_.26_RT|ADT & RT]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
''Note: these are clinical trials that did not specify a particular therapy to be used for androgen deprivation. See papers for details; the below are examples.''
====Hormonotherapy====
*ADT with ONE of the following:
**[[:Category:GnRH agonists|LHRH agonist/analogue]] 
**[[:Category:GnRH antagonists|LHRH antagonist]]
**[[Endocrine_ablation_surgery#Bilateral_orchiectomy|Bilateral orchiectomy]]

===References===
# '''NCIC CTG PR.3/UK MRC PR07:''' Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W; NCIC CTG PR3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011 Dec 17;378(9809):2104-11. Epub 2011 Nov 2. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61095-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243932/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22056152 PubMed]

==ADT & RT {{#subobject:514ac2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ADT & RT: '''<u>A</u>'''ndrogen '''<u>D</u>'''eprivation '''<u>T</u>'''herapy & '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:4aac55|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://jamanetwork.com/journals/jama/fullarticle/199273 d'Amico et al. 2004]
| style="background-color:#1a9851" |Phase III (E)
|[[Prostate_cancer_-_historical#Radiation_therapy|RT]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.redjournal.org/article/S0360-3016(08)00845-6/fulltext Rosenthal et al. 2008 (RTOG 9902)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa0810095 Bolla et al. 2009 (EORTC 22961)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243932/ Warde et al. 2011 (NCIC CTG PR.3/UK MRC PR07)]
| style="background-color:#1a9851" |Phase III (E)
|[[#ADT_2|ADT]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.sciencedirect.com/science/article/pii/S0302283812004253 Mottet et al. 2012]
| style="background-color:#1a9851" |Phase III (E)
|[[#ADT_2|ADT]]
| style="background-color:#1a9850" |Superior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.58.0662 Pisansky et al. 2014 (RTOG 9910)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70045-8/fulltext Zapatero et al. 2015 (DART01/05 GICOR)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.2015.64.8055 Bolla et al. 2016 (EORTC 22991)]
| style="background-color:#1a9851" |Phase III (E)
|[[Prostate_cancer_-_historical#Radiation_therapy|RT]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: these are clinical trials that did not specify a particular drug to be used for androgen deprivation. See papers for details.''
====Preceding treatment====
*RTOG 9902 & DART01/05 GICOR: [[#ADT|ADT]] x 8 weeks
*RTOG 9910: [[#ADT|ADT]] x 8 weeks versus [[#ADT|ADT]] x 28 weeks
====Hormonoradiotherapy====
*[[:Category:GnRH agonists|LHRH agonist]]
*Some protocols: [[Endocrine_ablation_surgery#Bilateral_orchiectomy|Bilateral orchiectomy]]
*Some protocols: [[Bicalutamide (Casodex)]] or [[Flutamide (Eulexin)]]
*[[External beam radiotherapy]]

'''8-week course'''
====Subsequent treatment====
*RTOG 9902: ADT x 2 y versus TEE x 4, then ADT x 2 y
*EORTC 22961: ADT for 6 months versus ADT for 36 months
*DART01/05 GICOR: ADT for 24 months versus no further treatment

===References===
# D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004 Aug 18;292(7):821-7. [https://jamanetwork.com/journals/jama/fullarticle/199273 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15315996 PubMed]
# '''RTOG 9902:''' Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R, Kerlin KJ, Michalski JM, Sandler HM; Radiation Therapy Oncology Group Trial 9902. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):672-8. Epub 2008 Nov 5. [https://www.redjournal.org/article/S0360-3016(08)00845-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18990504 PubMed]
## '''Update:''' Rosenthal SA, Hunt D, Sartor AO, Pienta KJ, Gomella L, Grignon D, Rajan R, Kerlin KJ, Jones CU, Dobelbower M, Shipley WU, Zeitzer K, Hamstra DA, Donavanik V, Rotman M, Hartford AC, Michalski J, Seider M, Kim H, Kuban DA, Moughan J, Sandler H. A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: final results of radiation therapy oncology group phase 3 randomized trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):294-302. Epub 2015 Jul 21. [https://www.redjournal.org/article/S0360-3016(15)00552-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719152/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26209502 PubMed]
# '''EORTC 22961:''' Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pi√©rart M, Mauer ME, Collette L; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009 Jun 11;360(24):2516-27. [https://www.nejm.org/doi/10.1056/NEJMoa0810095 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19516032 PubMed]
# '''NCIC CTG PR.3/UK MRC PR07:''' Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W; NCIC CTG PR3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011 Dec 17;378(9809):2104-11. Epub 2011 Nov 2. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61095-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243932/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22056152 PubMed]
# Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol. 2012 Aug;62(2):213-9. Epub 2012 Apr 3. [https://www.sciencedirect.com/science/article/pii/S0302283812004253 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/22502942 PubMed]
# '''RTOG 9910:''' Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 1;33(4):332-9. Epub 2014 Dec 22. [http://ascopubs.org/doi/full/10.1200/JCO.2014.58.0662 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302214/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25534388 PubMed]
# '''DART01/05 GICOR:''' Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodr√≠guez MA, Macias V, Pedro Olive A, Casas F, Boladeras A, de Vidales CM, Vazquez de la Torre ML, Vill√† S, Perez de la Haza A, Calvo FA. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015 Mar;16(3):320-7. Epub 2015 Feb 19. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70045-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25702876 PubMed]
# '''EORTC 22991:''' Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh AC, Collette L. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol. 2016 May 20;34(15):1748-56. Epub 2016 Mar 14. [http://ascopubs.org/doi/abs/10.1200/JCO.2015.64.8055 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26976418 PubMed]

==Flutamide, Goserelin, RT {{#subobject:2 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:2 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.goldjournal.net/article/S0090-4295(99)80053-3/pdf Pilepich et al. 1995]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Radiation_therapy|RT]]
|style="background-color:#1a9850"|Superior DFS
|-
|[http://www.redjournal.org/article/S0360-3016(01)01579-6/fulltext Pilepich et al. 2001 (RTOG 86-10)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Radiation_therapy|RT]]
|style="background-color:#91cf60"|Seems to have superior cause-specific mortality
|-
|[http://jco.ascopubs.org/content/21/21/3972.long Hanks et al. 2003 (RTOG 92-02)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(05)70348-X/abstract Denham et al. 2005 (TTROG 96.01)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Flutamide & Goserelin x 6 mo, RT
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[Prostate_cancer_-_historical#Radiation_therapy|RT]]
|style="background-color:#1a9850"|Superior EFS
|-
|[http://jama.ama-assn.org/content/299/3/289.long D'Amico et al. 2008 (DFCI 95-096)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Radiation_therapy|RT]]
|style="background-color:#1a9850"|Superior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1012348 Jones et al. 2011 (RTOG 94-08)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Radiation_therapy|RT]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Hormonoradiotherapy====
*[[Flutamide (Eulexin)]] 250 mg PO three times per day, to start 2 months prior to radiation therapy and to continue at least through the end of radiation therapy
*[[Goserelin (Zoladex)]] 3.6 mg SC once every 4 weeks, to start 2 months prior to radiation therapy and to continue at least through the end of radiation therapy
*[[External beam radiotherapy]] is started 2 months after start of androgen deprivation therapy (ADT), 1.8 to 2 Gy per fraction, with an initial 44 to 46 Gy to the pelvis, then an additional conedown to the prostate that resulted in a total dose of 65 to 70 Gy
====Subsequent treatment====
*RTOG 92-02: [[#Goserelin_monotherapy|adjuvant goserelin]] x 2 y versus [[#Observation|no further treatment]]

===References===
# Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Soloway MS. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995 Apr;45(4):616-23. [https://www.goldjournal.net/article/S0090-4295(99)80053-3/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7716842 PubMed]
# '''RTOG 86-10:''' Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52. [http://www.redjournal.org/article/S0360-3016(01)01579-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11483335 PubMed]
## '''Update:''' Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008 Feb 1;26(4):585-91. Epub 2008 Jan 2. [http://jco.ascopubs.org/content/26/4/585.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18172188 PubMed]
# '''RTOG 92-02:''' Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003 Nov 1;21(21):3972-8. Erratum in: J Clin Oncol. 2004 Jan 15;22(2):386. [http://jco.ascopubs.org/content/21/21/3972.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14581419 PubMed]
## '''Update:''' Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504. Epub 2008 Apr 14. [http://jco.ascopubs.org/content/26/15/2497.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18413638 PubMed]
## '''Update:''' Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM. Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303. Epub 2017 Feb 12. [https://www.ncbi.nlm.nih.gov/pubmed/28463149 PubMed]
# '''TTROG 96.01:''' Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, D'Este C; Trans-Tasman Radiation Oncology Group. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005 Nov;6(11):841-50. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(05)70348-X/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16257791 PubMed]
## '''Update:''' Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011 May;12(5):451-9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70063-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21440505 PubMed]
# '''DFCI 95-096:''' D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008 Jan 23;299(3):289-95. [http://jama.ama-assn.org/content/299/3/289.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18212313 PubMed] content property of [http://hemonc.org HemOnc.org]
## '''Update:''' D'Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA. 2015 Sep 22-29;314(12):1291-3. [https://jamanetwork.com/journals/jama/fullarticle/2442924 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26393854 PubMed]
# '''RTOG 94-08:''' Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011 Jul 14;365(2):107-18. [https://www.nejm.org/doi/full/10.1056/NEJMoa1012348 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21751904 PubMed]

==Flutamide, Leuprolide, RT {{#subobject:3 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 4 months of ADT {{#subobject:3 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1012348 Jones et al. 2011 (RTOG 94-08)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Radiation_therapy|RT]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Hormonoradiotherapy====
*[[Flutamide (Eulexin)]] 250 mg PO three times per day x 4 months, to start 2 months prior to radiation therapy
*[[Leuprolide (Lupron)]] 7.5 mg SC once every 4 weeks x 4 months, to start 2 months prior to radiation therapy 
*[[External beam radiotherapy]] is started 2 months after start of androgen deprivation therapy (ADT), 1.8 to 2 Gy per fraction, with an initial 44 to 46 Gy to the pelvis, then an additional conedown to the prostate that resulted in a total dose of 65 to 70 Gy

===Variant #2, indefinite ADT {{#subobject:5bddaf |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61815-2/fulltext Widmark et al. 2008 (SPCG-7/SFUO-3)]
|style="background-color:#1a9851"|Phase III (C)
|Flutamide & Leuprolide
| style="background-color:#1a9850" |Superior OS
|-
|}
====Hormonoradiotherapy====
*[[Flutamide (Eulexin)]] 250 mg PO three times per day, to start 3 months prior to radiation therapy
*[[Leuprolide (Lupron)]] by one of the following, to start 3 months prior to radiation therapy:
**3.75 mg SC once per month for 3 months
**11.25 mg SC once
*[[External beam radiotherapy]] 50 Gy + 20 Gy boost (total dose minimum of 70 Gy)

===References===
# '''RTOG 94-08:''' Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011 Jul 14;365(2):107-18. [https://www.nejm.org/doi/full/10.1056/NEJMoa1012348 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21751904 PubMed]
# '''SPCG-7/SFUO-3:''' Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Foss√• SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009 Jan 24;373(9660):301-8. Epub 2008 Dec 16. Erratum in: Lancet. 2009 Apr 4;373(9670):1174. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61815-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19091394 PubMed]

==Goserelin & RT {{#subobject:1 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy

===Regimen {{#subobject:1 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/15/3/1013.long Pilepich et al. 2005 (RTOG 85-31)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Radiation_therapy|RT]]
|style="background-color:#1a9850"|Superior DFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199707313370502 Bolla et al. 1997 (EORTC 22863)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Radiation_therapy|RT]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Hormonoradiotherapy====
*[[Goserelin (Zoladex)]] 3.6 mg SC once every 4 weeks, to start during the last week of radiation therapy and to continue indefinitely or until progression
*[[External beam radiotherapy]], 1.8 to 2 Gy per fraction, with an initial 44 to 46 Gy to the pelvis, then an additional boost to the prostate that resulted in a total dose of 65 to 70 Gy in definitive radiation patients; 60 to 65 Gy total dose for post-prostatectomy patients

'''Continued indefinitely'''

===References===
# '''RTOG 85-31:''' Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997 Mar;15(3):1013-21. [http://jco.ascopubs.org/content/15/3/1013.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9060541 PubMed]
## '''Update:''' Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):937-46. [http://www.redjournal.org/article/S0360-3016%2800%2901516-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11240234 PubMed]
## '''Update:''' Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90. [http://www.redjournal.org/article/S0360-3016(04)02468-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15817329 PubMed]
# '''EORTC 22863:''' Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997 Jul 31;337(5):295-300. [https://www.nejm.org/doi/full/10.1056/NEJM199707313370502 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9233866 PubMed]
## '''Update:''' Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002 Jul 13;360(9327):103-6. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)09408-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12126818 PubMed]

=Adjuvant hormonal therapy=
==Bicalutamide & Goserelin {{#subobject:611758|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:bdfd60|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107759/ Dorff et al. 2011 (SWOG S9921)]
|style="background-color:#1a9851"|Phase III (C)
|ADT & Mitoxantrone
|style="background-color:#d3d3d3"|Not reported
|-
|}
''Dosing details are not available in the manuscript; this is the common dosing used.''
====Preceding treatment====
*[[Surgery#Radical_prostatectomy|Radical prostatectomy]]
====Hormonotherapy====
*[[Bicalutamide (Casodex)]] 50 mg PO once per day
*[[Goserelin (Zoladex)]] 10.8 mg SC once every 12 weeks

'''2-year course'''

===References===
# '''SWOG S9921:''' Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20;29(15):2040-5. Epub 2011 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2010.32.2776 link to original article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107759/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21502546 PubMed]

==Goserelin monotherapy {{#subobject:267ff5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:53d064|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199912093412401 Messing et al. 1999 (ECOG E3886)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|No further treatment]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[http://jco.ascopubs.org/content/21/21/3972.long Hanks et al. 2003 (RTOG 92-02)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|No further treatment]]
|style="background-color:#91cf60"|Seems to have superior OS (*)
|-
|}
''Efficacy of RTOG 92-02 based on the 2017 update.''
====Preceding treatment====
*ECOG E3886: [[Surgery#Radical_prostatectomy|Radical prostatectomy]]
*RTOG 92-02: [[#Flutamide.2C_Goserelin.2C_RT|Flutamide, Goserelin, RT]]
====Hormonotherapy====
*[[Goserelin (Zoladex)]] 3.6 mg SC once per month

'''2-year course (RTOG 92-02) or until rising PSA detected (ECOG E3886)'''

===References===
# '''ECOG E3886:''' Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999 Dec 9;341(24):1781-8. [https://www.nejm.org/doi/full/10.1056/NEJM199912093412401 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10588962 PubMed]
## '''Update:''' Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D; Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006 Jun;7(6):472-9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(06)70700-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16750497 PubMed]
# '''RTOG 92-02:''' Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003 Nov 1;21(21):3972-8. Erratum in: J Clin Oncol. 2004 Jan 15;22(2):386. [http://jco.ascopubs.org/content/21/21/3972.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14581419 PubMed]
## '''Update:''' Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504. Epub 2008 Apr 14. [http://jco.ascopubs.org/content/26/15/2497.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18413638 PubMed]
## '''Update:''' Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM. Duration of androgen deprivation in locally advanced prostate cancer: Long-term update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303. Epub 2017 Feb 12. [https://www.ncbi.nlm.nih.gov/pubmed/28463149 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199912093412401 Messing et al. 1999 (ECOG E3886)]
|style="background-color:#1a9851"|Phase III (C)
|1. Bilateral orchiectomy<br> 2. [[#Goserelin_monotherapy|Goserelin]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[http://jco.ascopubs.org/content/21/21/3972.long Hanks et al. 2003 (RTOG 92-02)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Goserelin_monotherapy|Goserelin]]
|style="background-color:#fc8d59"|Seems to have inferior OS (*)
|-
|}
''Efficacy of RTOG 92-02 based on the 2017 update. No further treatment after definitive therapy''
====Preceding treatment====
*ECOG E3886: [[Surgery#Radical_prostatectomy|Radical prostatectomy]]
*RTOG 92-02: [[#Flutamide.2C_Goserelin.2C_RT|Flutamide, Goserelin, RT]]

===References===
# '''ECOG E3886:''' Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999 Dec 9;341(24):1781-8. [https://www.nejm.org/doi/full/10.1056/NEJM199912093412401 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10588962 PubMed]
## '''Update:''' Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D; Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006 Jun;7(6):472-9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(06)70700-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16750497 PubMed]
# '''RTOG 92-02:''' Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003 Nov 1;21(21):3972-8. Erratum in: J Clin Oncol. 2004 Jan 15;22(2):386. [http://jco.ascopubs.org/content/21/21/3972.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14581419 PubMed]
## '''Update:''' Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504. Epub 2008 Apr 14. [http://jco.ascopubs.org/content/26/15/2497.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18413638 PubMed]
## '''Update:''' Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM. Duration of androgen deprivation in locally advanced prostate cancer: Long-term update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303. Epub 2017 Feb 12. [https://www.ncbi.nlm.nih.gov/pubmed/28463149 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921119/ Bosland et al. 2013]
| style="background-color:#1a9851" |Phase III (C)
|Soy protein isolate
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No further treatment after definitive therapy''
====Preceding treatment====
*[[Surgery#Radical_prostatectomy|Radical prostatectomy]]
===References===
# Bosland MC, Kato I, Zeleniuch-Jacquotte A, Schmoll J, Enk Rueter E, Melamed J, Kong MX, Macias V, Kajdacsy-Balla A, Lumey LH, Xie H, Gao W, Walden P, Lepor H, Taneja SS, Randolph C, Schlicht MJ, Meserve-Watanabe H, Deaton RJ, Davies JA. Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. JAMA. 2013 Jul 10;310(2):170-8. [https://jamanetwork.com/journals/jama/fullarticle/1710457 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921119/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23839751 PubMed]

=Salvage ADT & radiotherapy=
==Bicalutamide & RT {{#subobject:2c64f0 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:4f2e28 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444881/ Shipley et al. 2017 (RTOG 9601)]
|style="background-color:#1a9851"|Phase III (E)
|RT
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Preceding treatment====
*[[Surgery#Prostatectomy_with_lymphadenectomy|Prostatectomy with lymphadenectomy]], with a postoperative detectable PSA level of 0.2 to 4.0 ng/mL
====Endocrine & Radiotherapy====
*[[Bicalutamide (Casodex)]] 150 mg PO once per day for 24 months
*[[External beam radiotherapy]], 64.8 Gy in 36 daily fractions of 1.80 Gy, 5 days per week

'''One course'''

===References===
# '''RTOG 9601:''' Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017 Feb 2;376(5):417-428. [https://www.nejm.org/doi/full/10.1056/NEJMoa1607529 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444881/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28146658 PubMed]

==Goserelin & RT {{#subobject:88575c |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:fac0bd |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00111-X/fulltext Carrie et al. 2016 (GETUG-AFU 16)]
|style="background-color:#1a9851"|Phase III (E)
|Salvage RT
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Preceding treatment====
*[[Surgery#Prostatectomy|Prostatectomy]], with rising PSA
====Endocrine & Radiotherapy====
*[[Goserelin (Zoladex)]] 0.8 mg SC once on the first day of RT, then once 3 months later
*[[External beam radiotherapy]], 66 Gy in 33 daily fractions of 2 Gy, 5 days per week

'''7-week course'''

===References===
# '''GETUG-AFU 16:''' Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Cr√©hange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016 Jun;17(6):747-756. Epub 2016 May 6. Erratum in: Lancet Oncol. 2016 Jun;17 (6):e223. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00111-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27160475 PubMed]

=Hormonal therapy for non-metastatic castrate sensitive disease=
==ADT {{#subobject:6e0da9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ADT: '''<u>A</u>'''ndrogen '''<u>D</u>'''eprivation '''<u>T</u>'''herapy
===Regimen {{#subobject:0415d3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.europeanurology.com/article/S0302-2838(15)00977-X/fulltext Schulman et al. 2015 (ICELAND)]
|style="background-color:#1a9851"|Phase III (C)
|Intermittent ADT
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00107-8/fulltext Duchesne et al. 2016 (TROG 03.06/TOAD)]
|style="background-color:#1a9851"|Phase III (E)
|Delayed ADT
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Note: these are clinical trials that did not specify a particular drug to be used for androgen deprivation. See papers for details.''
====Hormonotherapy====
*[[:Category:GnRH agonists|LHRH agonist]]
*[[Bicalutamide (Casodex)]] or [[Flutamide (Eulexin)]]

'''Continued indefinitely'''
===References===
# '''ICELAND:''' Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, Warnack W, Persad R, Salagierski M, G√≥mez Veiga F, Baskin-Bey E, L√≥pez B, Tombal B. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (ICELAND). Eur Urol. 2016 Apr;69(4):720-727. Epub 2015 Oct 29. [https://www.europeanurology.com/article/S0302-2838(15)00977-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26520703 PubMed]
# '''TROG 03.06/TOAD:''' Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D'Este C, Frydenberg M, King M, Ledwich L, Loblaw A, Malone S, Millar J, Milne R, Smith RG, Spry N, Stockler M, Syme RA, Tai KH, Turner S. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016 Jun;17(6):727-737. Epub 2016 May 4. Erratum in: Lancet Oncol. 2016 Jun;17 (6):e223. Lancet Oncol. 2017 Sep;18(9):e510. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00107-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27155740 PubMed]

=Hormonal therapy for non-metastatic castrate resistant disease=
==Apalutamide monotherapy {{#subobject:a70eae |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:#e085c7 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence|Metastasis-free survival]]
!Comparator [[Levels_of_Evidence|Metastasis-free survival]]
!Pt Population
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1715546 Smith et al. 2017 (SPARTAN)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Placebo|Placebo]]
|style="background-color:#1a9850"|Superior MFS
|40.5 months
|16.2 months
|Castrate-resistant, non-metastatic, PSA doubling time <10 months
|-
|}
====Hormonotherapy====
*[[Apalutamide (Erleada)]] 240 mg PO once per day
**Patients should concurrently be receiving [[:Category:Endocrine therapy|GnRH analog]] or have had [[Endocrine_ablation_surgery#Bilateral_orchiectomy|bilateral orchiectomy]]

'''Continued indefinitely'''

===References===
# '''SPARTAN:''' Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018 Apr 12;378(15):1408-1418. [https://www.nejm.org/doi/10.1056/NEJMoa1715546 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1715546/suppl_file/nejmoa1715546_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29420164 PubMed]

==Enzalutamide monotherapy {{#subobject:d34e0b |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:#80614f |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1800536 Hussain et al. 2018 (PROSPER)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Placebo|Placebo]]
|style="background-color:#1a9850"|Superior MFS
|-
|}
''Patients had castrate-resistant, non-metastatic, prostate cancer with PSA doubling time less than 10 months.''
====Hormonotherapy====
*[[Enzalutamide (Xtandi)]] 160 mg PO once per day
**Patients should concurrently be receiving ADT or have had [[Endocrine_ablation_surgery#Bilateral_orchiectomy|bilateral orchiectomy]]

'''Continued indefinitely'''

===References===
# '''PROSPER:''' Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018 Jun 28;378(26):2465-2474. [https://www.nejm.org/doi/full/10.1056/NEJMoa1800536 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29949494 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085548/ Nelson et al. 2008]
| style="background-color:#1a9851" |Phase III (C)
|Atrasentan
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No active antineoplastic therapy.''
===References===
# Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M; Atrasentan Phase 3 Study Group. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008 Nov 1;113(9):2478-87. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.23864 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085548/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18785254 PubMed]

=Hormonal therapy for metastatic or locally advanced disease=
==ADT {{#subobject:45fc98|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ADT: '''<u>A</u>'''ndrogen '''<u>D</u>'''eprivation '''<u>T</u>'''herapy
===Regimen {{#subobject:bd66bd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://jurology.com/retrieve/pii/S0022534705615236 Schr√∂der et al. 2004 (EORTC 30846)]
|style="background-color:#1a9851"|Phase III (C)
|Delayed ADT
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398767/ James et al. 2012 (STAMPEDE)]
|style="background-color:#1a9851"|Phase III (C)
|ADT & Celecoxib
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70560-0/fulltext Gravis et al. 2013 (GETUG-AFU 15)]
|style="background-color:#1a9851"|Phase III (C)
|[[#ADT_.26_Docetaxel|ADT & Docetaxel]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00011-X/fulltext Fizazi et al. 2015 (GETUG 12)]
|style="background-color:#1a9851"|Phase III (C)
|ADT, Docetaxel, Estramustine
| style="background-color:#fc8d59" |Seems to have inferior RFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1503747 Sweeney et al. 2015 (CHAARTED)]
|style="background-color:#1a9851"|Phase III (C)
|[[#ADT_.26_Docetaxel|ADT & Docetaxel]]
| style="background-color:#d73027" |Inferior OS (*)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800035/ James et al. 2015 (STAMPEDE)]
|style="background-color:#1a9851"|Phase III (C)
|[[#ADT_.26_Docetaxel|ADT & Docetaxel]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://link.springer.com/article/10.1007%2Fs10147-016-1037-2 Kamba et al. 2016 (ZAPCA)]
|style="background-color:#1a9851"|Phase III (C)
|ADT & Zoledronic acid
| style="background-color:#fee08b" |Might have inferior TTTF
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533216 James et al. 2017 (STAMPEDE)]
|style="background-color:#1a9851"|Phase III (C)
|[[#ADT_.26_Abiraterone|ADT & Abiraterone]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1704174 Fizazi et al. 2017 (LATITUDE)]
|style="background-color:#1a9851"|Phase III (C)
|[[#ADT_.26_Abiraterone|ADT & Abiraterone]]
| style="background-color:#d73027" |Inferior OS
|-
|}
''Note: these are clinical trials that did not specify a particular therapy to be used for androgen deprivation. See papers for details; the below are examples. In the 2018 update of CHAARTED, only patients with high-volume disease had inferior survival in the control arm.''
====Hormonotherapy====
*ADT with ONE of the following:
**[[:Category:GnRH agonists|LHRH agonist/analogue]] 
**[[:Category:GnRH antagonists|LHRH antagonist]]
**[[Endocrine_ablation_surgery#Bilateral_orchiectomy|Bilateral orchiectomy]]

'''Continued indefinitely'''
===References===
# '''EORTC 30846:''' Schr√∂der FH, Kurth KH, Foss√• SD, Hoekstra W, Karthaus PP, Debois M, Collette L; Members of the European Organisation for the Research and Treatment of Cancer Genito-urinary Group. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study. J Urol. 2004 Sep;172(3):923-7. [https://jurology.com/retrieve/pii/S0022534705615236 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15310999 PubMed]
# '''STAMPEDE:''' James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MK; STAMPEDE investigators. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 2012 May;13(5):549-58. Epub 2012 Mar 26. Erratum in: Lancet Oncol. 2013 Jan;14(1):e5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70088-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398767/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22452894 PubMed]
# '''GETUG-AFU 15:''' Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Th√©odore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Feb;14(2):149-58. Epub 2013 Jan 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70560-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23306100 PubMed]
## '''Update:''' Gravis G, Boher JM, Joly F, Souli√© M, Albiges L, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Th√©odore C, Deplanque G, Ferrero JM, Culine S, Mourey L, Beuzeboc P, Habibian M, Oudard S, Fizazi K; GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016 Aug;70(2):256-62. Epub 2015 Nov 21. [http://www.europeanurology.com/article/S0302-2838(15)01103-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26610858 PubMed]
# '''GETUG 12:''' Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fl√©chon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 2015 Jul;16(7):787-94. Epub 2015 May 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00011-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26028518 PubMed]
# '''CHAARTED:''' Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015 Aug 20;373(8):737-46. Epub 2015 Aug 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1503747 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26244877 Pubmed]
## '''Update:''' Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018 Apr 10;36(11):1080-1087. Epub 2018 Jan 31. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.3657 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891129/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29384722 PubMed]
## '''QoL analysis:''' Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ. Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. J Clin Oncol. 2018 Apr 10;36(11):1088-1095. Epub 2018 Mar 9. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.3335 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891128/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29522362 PubMed]
# '''STAMPEDE:''' James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1163-77. Epub 2015 Dec 21. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01037-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800035/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26719232 PubMed]
# '''ZAPCA:''' Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, Fujimoto K, Kawanishi H, Sato F, Narita S, Satoh T, Saito H, Sugimoto M, Teishima J, Masumori N, Egawa S, Sakai H, Okada Y, Terachi T, Ogawa O; ZAPCA Study Group. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. Int J Clin Oncol. 2017 Feb;22(1):166-173. Epub 2016 Sep 10. [https://link.springer.com/article/10.1007%2Fs10147-016-1037-2 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27614621 PubMed]
# '''STAMPEDE:''' James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017 Jul 27;377(4):338-351. Epub 2017 Jun 3. [https://www.nejm.org/doi/full/10.1056/NEJMoa1702900 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533216 link to PMC article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1702900/suppl_file/nejmoa1702900_protocol.pdf supplementary protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28578639 PubMed]
# '''LATITUDE:''' Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, √ñzg√ºroƒülu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017 Jul 27;377(4):352-360. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1704174 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1704174/suppl_file/nejmoa1704174_protocol.pdf supplementary protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28578607 PubMed]
## '''HRQoL analysis:''' Chi KN, Protheroe A, Rodr√≠guez-Antol√≠n A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Dami√£o R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 2018 Feb;19(2):194-206. Epub 2018 Jan 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30911-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29326030 PubMed]

==ADT & Abiraterone {{#subobject:02afb7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ADT & Abiraterone: '''<u>A</u>'''ndrogen '''<u>D</u>'''eprivation '''<u>T</u>'''herapy & Abiraterone
===Regimen {{#subobject:31ffca|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533216 James et al. 2017 (STAMPEDE)]
|style="background-color:#1a9851"|Phase III (E)
|[[#ADT_4|ADT]]
|style="background-color:#1a9850"|Superior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1704174 Fizazi et al. 2017 (LATITUDE)]
|style="background-color:#1a9851"|Phase III (E)
|[[#ADT_4|ADT]]
|style="background-color:#1a9850"|Superior OS
|-
|}
''Note: while LATITUDE allowed for a dose increase in prednisone, the FDA recommended dose is 5 mg PO once per day.''
====Hormonotherapy====
*[[Abiraterone (Zytiga)]] 1000 mg PO once per day
*ADT with ONE of the following:
**[[:Category:GnRH agonists|LHRH agonist/analogue]] 
**'''STAMPEDE only:''' [[:Category:GnRH antagonists|LHRH antagonist]]
**[[Endocrine_ablation_surgery#Bilateral_orchiectomy|Bilateral orchiectomy]]

====Supportive medications====
*Prevention of mineralocorticoid excess with ONE of the following:
**'''STAMPEDE except Switzerland:''' [[Prednisolone (Millipred)]] 5 mg PO once per day
**'''LATITUDE and STAMPEDE in Switzerland:''' [[Prednisone (Sterapred)]] 5 mg PO once per day
***'''LATITUDE:''' "dose increase of up to 10 mg/day is permitted to manage refractory mineralocorticoid related toxicities"

'''Continued until progression unless radiotherapy planned, in which case continued for up to 2 years'''

===References===
# '''STAMPEDE:''' James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017 Jul 27;377(4):338-351. Epub 2017 Jun 3. [https://www.nejm.org/doi/full/10.1056/NEJMoa1702900 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533216 link to PMC article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1702900/suppl_file/nejmoa1702900_protocol.pdf supplementary protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28578639 PubMed]
# '''LATITUDE:''' Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, √ñzg√ºroƒülu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017 Jul 27;377(4):352-360. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1704174 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1704174/suppl_file/nejmoa1704174_protocol.pdf supplementary protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28578607 PubMed]
## '''HRQoL analysis:''' Chi KN, Protheroe A, Rodr√≠guez-Antol√≠n A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Dami√£o R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 2018 Feb;19(2):194-206. Epub 2018 Jan 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30911-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29326030 PubMed]

==ADT & Docetaxel {{#subobject:EJCADTdoceR|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ADT & Docetaxel: '''<u>A</u>'''ndrogen '''<u>D</u>'''eprivation '''<u>T</u>'''herapy & Docetaxel
===Variant #1, 6 cycles {{#subobject:EJCADTdoceV|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1503747 Sweeney et al. 2015 (CHAARTED)]
|style="background-color:#1a9851"|Phase III (E)
|[[#ADT_4|ADT]]
|style="background-color:#1a9850"|Superior OS (*)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800035/ James et al. 2015 (STAMPEDE)]
|style="background-color:#1a9851"|Phase III (E)
|[[#ADT_4|ADT]]
|style="background-color:#1a9850"|Superior OS
|-
|}
''Patients already on androgen deprivation therapy were eligible to participate in CHAARTED if there was no evidence of disease progression and if they had started ADT no more than 120 days before randomization. In the 2018 update of CHAARTED, only patients with high-volume disease had superior survival in the experimental arm.''
====Chemohormonal therapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*ADT with ONE of the following:
**[[:Category:GnRH agonists|LHRH agonist/analogue]] 
**[[:Category:GnRH antagonists|LHRH antagonist]]
**[[Endocrine_ablation_surgery#Bilateral_orchiectomy|Bilateral orchiectomy]]
**Intermittent hormonal therapy was not allowed. Antiandrogens e.g. [[Bicalutamide (Casodex)|bicalutamide]] were allowed at the start of therapy "at the discretion of the investigator." 

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO given three times; 12 hours, 3 hours, and 1 hour before [[Docetaxel (Taxotere)]]
*Daily prednisone was not required
*At least calcium 500 mg and vitamin D 400 IU PO once per day

'''21-day cycle for up to 6 cycles'''

===Variant #2, 9 cycles {{#subobject:257951|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70560-0/fulltext Gravis et al. 2013 (GETUG-AFU 15)]
|style="background-color:#1a9851"|Phase III (E)
|[[#ADT_4|ADT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemohormonal therapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*ADT with one of the following:
**[[:Category:GnRH agonists|LHRH agonist/analogue]] with or without [[:Category:Nonsteroidal_androgen_receptor_inhibitors|nonsteroidal androgen receptor inhibitors]]
**[[Endocrine_ablation_surgery#Bilateral_orchiectomy|Bilateral orchiectomy]] with or without [[:Category:Nonsteroidal_androgen_receptor_inhibitors|nonsteroidal androgen receptor inhibitors]]

'''21-day cycle for up to 9 cycles'''

===References===
# '''GETUG-AFU 15:''' Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Th√©odore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Feb;14(2):149-58. Epub 2013 Jan 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70560-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23306100 PubMed]
## '''Update:''' Gravis G, Boher JM, Joly F, Souli√© M, Albiges L, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Th√©odore C, Deplanque G, Ferrero JM, Culine S, Mourey L, Beuzeboc P, Habibian M, Oudard S, Fizazi K; GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016 Aug;70(2):256-62. Epub 2015 Nov 21. [http://www.europeanurology.com/article/S0302-2838(15)01103-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26610858 PubMed]
# '''CHAARTED:''' Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015 Aug 20;373(8):737-46. Epub 2015 Aug 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1503747 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26244877 Pubmed]
## '''Update:''' Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018 Apr 10;36(11):1080-1087. Epub 2018 Jan 31. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.3657 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891129/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29384722 PubMed]
## '''QoL analysis:''' Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ. Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. J Clin Oncol. 2018 Apr 10;36(11):1088-1095. Epub 2018 Mar 9. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.3335 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891128/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29522362 PubMed]
# '''STAMPEDE:''' James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1163-77. Epub 2015 Dec 21. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01037-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800035/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26719232 PubMed]

==Bicalutamide monotherapy {{#subobject:5 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.karger.com/Article/Abstract/19634 Tyrrell et al. 1998]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Castration|Castration]]
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|[https://www.europeanurology.com/article/S0302-2838(02)00311-1/fulltext Iversen et al. 2002 (SPCG-6)]
|style="background-color:#1a9851"|Phase III (E)
|Placebo
| style="background-color:#1a9850" |Superior OS (*)
|-
|}
''Not approved for monotherapy in the United States. See combination regimens with goserelin & leuprolide. Reported efficacy for Tyrrell et al. 1998 is based on the 2000 update. Reported efficacy for SPCG-6 is based on the 2006 update and is only for the locally advanced subgroup.''
====Hormonotherapy====
*[[Bicalutamide (Casodex)]] 150 mg PO once per day

'''Continued indefinitely'''
===References===
# Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33(5):447-56. [https://www.karger.com/Article/Abstract/19634 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9643663 PubMed]
## '''Update:''' Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol. 2000 Nov;164(5):1579-82. [http://www.jurology.com/article/S0022-5347(05)67032-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11025708 PubMed]
# '''SPCG-6:''' Iversen P, Tammela TL, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P, Lundmo P, Rasmussen F, Johansson JE, Persson BE, Carroll K; Scandinavian Prostatic Cancer Group (SPCG). A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer: first report from the Scandinavian Prostatic Cancer Group Study No 6. Eur Urol. 2002 Sep;42(3):204-11. [https://www.europeanurology.com/article/S0302-2838(02)00311-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12234503 PubMed]
## '''Update:''' Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K; Scandinavian Prostatic Cancer Group. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol. 2004 Nov;172(5 Pt 1):1871-6. [https://www.jurology.com/article/S0022-5347(05)60880-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15540741 PubMed]
## '''Update:''' Iversen P, Johansson JE, Lodding P, Kylm√§l√§ T, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Armstrong J; Scandinavian Prostate Cancer Group. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol. 2006;40(6):441-52. [https://www.tandfonline.com/doi/abs/10.1080/00365590601017329 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17130095 PubMed]

==Bicalutamide & Goserelin {{#subobject:10 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:a8fe78|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jjco.oxfordjournals.org/content/34/1/20.full Akaza et al. 2004]
|style="background-color:#1a9851"|Phase III (E)
|1. [[#Goserelin_monotherapy_2|Goserelin]]<br> 2. [[#Leuprolide_monotherapy|Leuprolide]]
|style="background-color:#91cf60"|Seems to have superior OS (*)
|-
|}
''Note: efficacy is based on the 2009 update.''
====Hormonotherapy====
*[[Bicalutamide (Casodex)]] 80 mg PO once per day
*[[Goserelin (Zoladex)]] 3.6 mg SC once every 4 weeks

===Variant #2 {{#subobject:10 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.goldjournal.net/article/S0090-4295(99)80077-6/abstract Schellhammer et al. 1995 (Casodex Combination Study Group)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Bicalutamide_.26_Leuprolide|Bicalutamide & Leuprolide]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Flutamide_.26_Goserelin_2|Flutamide & Goserelin]]<br> 3. [[#Flutamide_.26_Leuprolide|Flutamide & Leuprolide]]
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|}
''Efficacy for the Casodex Combination Study Group is based on the 1997 final update.''
====Hormonotherapy====
*[[Bicalutamide (Casodex)]] 50 mg PO once per day
*[[Goserelin (Zoladex)]] 3.6 mg SC once every 4 weeks

'''Continued indefinitely'''
===References===
# '''Casodex Combination Study Group:''' Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer; Casodex Combination Study Group. Urology. 1995 May;45(5):745-52. [http://www.goldjournal.net/article/S0090-4295(99)80077-6/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7538237 PubMed]
## '''Update:''' Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma: analysis of time to progression; CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. [https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19961115)78:10%3C2164::AID-CNCR18%3E3.0.CO;2-X/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8918410 PubMed]
## '''Update:''' Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G; Casodex Combination Study Group. A controlled trial of Casodex (bicalutamide) vs flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Eur Urol. 1996;29 Suppl 2:105-9. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8717471 PubMed]
## '''Update:''' Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ; Casodex Combination Study Group. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology. 1997 Sep;50(3):330-6. [https://www.goldjournal.net/article/S0090-4295(97)00279-3/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9301693 PubMed]
# Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda A, Arai Y, Usami M, Naito S, Kanetake H, Ohashi Y. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol. 2004 Jan;34(1):20-8. [http://jjco.oxfordjournals.org/content/34/1/20.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15020659 PubMed]
## '''Update:''' Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y; Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009 Aug 1;115(15):3437-45. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.24395 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19536889 PubMed]

==Bicalutamide & Leuprolide {{#subobject:13 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:28699c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jjco.oxfordjournals.org/content/34/1/20.full Akaza et al. 2004]
|style="background-color:#1a9851"|Phase III (E)
|1. [[#Goserelin_monotherapy|Goserelin]]<br> 2. [[#Leuprolide_monotherapy|Leuprolide]]
|style="background-color:#91cf60"|Seems to have superior OS (*)
|-
|}
''Note: efficacy is based on the 2009 update.''
====Hormonotherapy====
*[[Bicalutamide (Casodex)]] 80 mg PO once per day
*[[Leuprolide (Lupron)|Leuprolide (Lupron) 1-month depot]] 3.75 mg SC once every 4 weeks

===Variant #2 {{#subobject:13 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.goldjournal.net/article/S0090-4295(99)80077-6/abstract Schellhammer et al. 1995 (Casodex Combination Study Group)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Bicalutamide_.26_Goserelin_2|Bicalutamide & Goserelin]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Flutamide_.26_Goserelin_2|Flutamide & Goserelin]]<br> 3. [[#Flutamide_.26_Leuprolide|Flutamide & Leuprolide]]
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|}
''Efficacy for the Casodex Combination Study Group is based on the 1997 final update.''
====Hormonotherapy====
*[[Bicalutamide (Casodex)]] 50 mg PO once per day
*[[Leuprolide (Lupron)|Leuprolide (Lupron) 1-month depot]] 7.5 mg IM once every 4 weeks

'''Continued indefinitely'''
===References===
# '''Casodex Combination Study Group:''' Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer; Casodex Combination Study Group. Urology. 1995 May;45(5):745-52. [http://www.goldjournal.net/article/S0090-4295(99)80077-6/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7538237 PubMed]
## '''Update:''' Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma: analysis of time to progression; CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. [https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19961115)78:10%3C2164::AID-CNCR18%3E3.0.CO;2-X/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8918410 PubMed]
## '''Update:''' Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G; Casodex Combination Study Group. A controlled trial of Casodex (bicalutamide) vs flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Eur Urol. 1996;29 Suppl 2:105-9. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8717471 PubMed]
## '''Update:''' Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ; Casodex Combination Study Group. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology. 1997 Sep;50(3):330-6. [https://www.goldjournal.net/article/S0090-4295(97)00279-3/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9301693 PubMed]
# Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda A, Arai Y, Usami M, Naito S, Kanetake H, Ohashi Y. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol. 2004 Jan;34(1):20-8. [http://jjco.oxfordjournals.org/content/34/1/20.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15020659 PubMed]
## '''Update:''' Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y; Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009 Aug 1;115(15):3437-45. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.24395 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19536889 PubMed]

==Degarelix monotherapy {{#subobject:7 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Degarelix (Firmagon) in prostate cancer]]
===Variant #1, 240/80 {{#subobject:7 |Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2008.08183.x/full Klotz et al. 2008 (CS21)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Degarelix 240/160
|style="background-color:#eeee01"|Non-inferior testosterone suppression
|-
|2. [[#Leuprolide_monotherapy|Leuprolide]]
|style="background-color:#eeee01"|Non-inferior testosterone suppression
|-
|}
====Hormonotherapy====
*[[Degarelix (Firmagon)]] 240 mg (given as 2 x 120 mg injections) SC once, then 80 mg SC once every 28 days

'''Continued indefinitely'''

===Variant #2, 240/160 {{#subobject:7b |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2008.08183.x/full Klotz et al. 2008 (CS21)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Degarelix 240/80
|style="background-color:#eeee01"|Non-inferior testosterone suppression
|-
|2. [[#Leuprolide_monotherapy|Leuprolide]]
|style="background-color:#eeee01"|Non-inferior testosterone suppression
|-
|}
====Hormonotherapy====
*[[Degarelix (Firmagon)]] 240 mg (given as 2 x 120 mg injections) SC once, then 160 mg SC once every 28 days

'''Continued indefinitely'''

===Variant #3, 240/480 {{#subobject:01864f |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989846/ Ozono et al. 2018 (3550-CL-0010)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Goserelin_monotherapy_2|Goserelin]]
|style="background-color:#eeee01"|Non-inferior testosterone suppression
|-
|}
====Hormonotherapy====
*[[Degarelix (Firmagon)]] 240 mg SC once, then after 28 days, 480 mg SC once every 84 days

'''Continued indefinitely'''

===References===
# '''CS21:''' Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schr√∂der FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8. [https://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2008.08183.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19035858 PubMed]
## '''Update:''' Tombal B, Miller K, Boccon-Gibod L, Schr√∂der F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010 May;57(5):836-42. Epub 2009 Nov 20. [http://www.europeanurology.com/article/S0302-2838%2809%2901171-3 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19962227 PubMed]
# '''3550-CL-0010:''' Ozono S, Tsukamoto T, Naito S, Horie S, Ohashi Y, Uemura H, Yokomizo Y, Fukasawa S, Kusuoka H, Akazawa R, Saito M, Akaza H. Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: a phase III study. Cancer Sci. 2018 Jun;109(6):1920-1929. Epub 2018 May 23. [https://onlinelibrary.wiley.com/doi/abs/10.1111/cas.13600 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989846/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29624800 PubMed]

==Flutamide monotherapy {{#subobject:8 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/9412794 Boccon-Gibod et al. 1997]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Castration|Bilateral orchiectomy]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.1.62 Foss√• et al. 2001 (EORTC 30903)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Prednisone_monotherapy|Prednisone]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Not approved for monotherapy in the United States. See combination regimens with Goserelin & Leuprolide.''
====Hormonotherapy====
*[[Flutamide (Eulexin)]] 250 mg PO three times per day

'''Continued indefinitely'''
===References===
# Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol. 1997;32(4):391-5. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9412794 PubMed]
# '''EORTC 30903:''' Foss√• SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, Aaronson N, de Prijck L, Collette L. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001 Jan 1;19(1):62-71. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.1.62 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11134196 PubMed]

==Flutamide & Goserelin {{#subobject:11 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:11 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.goldjournal.net/article/0090-4295(93)90634-M/pdf Denis et al. 1993 (EORTC 30853)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Castration|Bilateral orchiectomy]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|rowspan=2|[http://www.goldjournal.net/article/S0090-4295(99)80077-6/abstract Schellhammer et al. 1995 (Casodex Combination Study Group)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Bicalutamide_.26_Goserelin_2|Bicalutamide & Goserelin]]<br> 2. [[#Bicalutamide_.26_Leuprolide|Bicalutamide & Leuprolide]]
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|3. [[#Flutamide_.26_Leuprolide|Flutamide & Leuprolide]]
|style="background-color:#d3d3d3"|Not reported
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682658/ Hussain et al. 2013 (SWOG-9346)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Intermittent_ADT|Intermittent ADT]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|}
''Efficacy for the Casodex Combination Study Group is based on the 1997 final update.''
====Hormonotherapy====
*[[Flutamide (Eulexin)]] 250 mg PO three times per day
*[[Goserelin (Zoladex)]] 3.6 mg SC once every 4 weeks

'''Continued indefinitely'''
===References===
# '''EORTC 30853:''' Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M; EORTC GU Group and EORTC Data Center. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology. 1993 Aug;42(2):119-29. [https://www.goldjournal.net/article/0090-4295(93)90634-M/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8367920 PubMed]
## '''Update:''' Denis LJ, Keuppens F, Smith PH, Whelan P, de Moura JL, Newling D, Bono A, Sylvester R; EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. Eur Urol. 1998;33(2):144-51. [https://www.ncbi.nlm.nih.gov/pubmed/9519355 PubMed]
# '''Casodex Combination Study Group:''' Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G; Casodex Combination Study Group. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology. 1995 May;45(5):745-52. [http://www.goldjournal.net/article/S0090-4295(99)80077-6/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7538237 PubMed]
## '''Update:''' Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ; CASODEX Combination Study Group. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma: analysis of time to progression. Cancer. 1996 Nov 15;78(10):2164-9. [https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19961115)78:10%3C2164::AID-CNCR18%3E3.0.CO;2-X/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8918410 PubMed]
## '''Update:''' Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G; Casodex Combination Study Group. A controlled trial of Casodex (bicalutamide) vs flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Eur Urol. 1996;29 Suppl 2:105-9. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8717471 PubMed]
## '''Update:''' Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ; Casodex Combination Study Group. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology. 1997 Sep;50(3):330-6. [https://www.goldjournal.net/article/S0090-4295(97)00279-3/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9301693 PubMed]
# '''SWOG-9346:''' Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4;368(14):1314-25. [https://www.nejm.org/doi/full/10.1056/NEJMoa1212299 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682658/ link to PMC article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1212299/suppl_file/nejmoa1212299_protocol.pdf supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23550669 PubMed]

==Flutamide & Leuprolide {{#subobject:14 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, daily Lupron {{#subobject:5b0861 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198908173210702 Crawford et al. 1989 (SWOG-8494)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Leuprolide_monotherapy|Leuprolide]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Note: this is likely of historic importance only, given the formulation of leuoprolide.''
====Hormonotherapy====
*[[Flutamide (Eulexin)]] 250 mg PO TID
*[[Leuprolide (Lupron)]] 1 mg SC once per day

'''Continued indefinitely'''

===Variant #2, 1-month depot Lupron {{#subobject:14 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://www.goldjournal.net/article/S0090-4295(99)80077-6/abstract Schellhammer et al. 1995 (Casodex Combination Study Group)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Bicalutamide_.26_Goserelin_2|Bicalutamide & Goserelin]]<br> 2. [[#Bicalutamide_.26_Leuprolide|Bicalutamide & Leuprolide]]
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|3. [[#Flutamide_.26_Goserelin_2|Flutamide & Goserelin]]
|style="background-color:#d3d3d3"|Not reported
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682658/ Hussain et al. 2013 (SWOG-9346)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Intermittent_ADT|Intermittent ADT]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|}
''Efficacy for the Casodex Combination Study Group is based on the 1997 final update.''
====Hormonotherapy====
*[[Flutamide (Eulexin)]] 250 mg PO TID
*[[Leuprolide (Lupron)|Leuprolide (Lupron) 1-month depot]] 7.5 mg IM once every 4 weeks

'''Continued indefinitely'''
===References===
# '''SWOG-8494:''' Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419-24. Erratum in: N Engl J Med 1989 Nov 16;321(20):1420. [https://www.nejm.org/doi/full/10.1056/NEJM198908173210702 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2503724 PubMed]
# '''Casodex Combination Study Group:''' Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer; Casodex Combination Study Group. Urology. 1995 May;45(5):745-52. [http://www.goldjournal.net/article/S0090-4295(99)80077-6/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7538237 PubMed]
## '''Update:''' Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma: analysis of time to progression; CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164-9. [https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19961115)78:10%3C2164::AID-CNCR18%3E3.0.CO;2-X/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8918410 PubMed]
## '''Update:''' Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G; Casodex Combination Study Group. A controlled trial of Casodex (bicalutamide) vs flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Eur Urol. 1996;29 Suppl 2:105-9. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8717471 PubMed]
## '''Update:''' Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ; Casodex Combination Study Group. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology. 1997 Sep;50(3):330-6. [https://www.goldjournal.net/article/S0090-4295(97)00279-3/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9301693 PubMed]
# '''SWOG-9346:''' Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4;368(14):1314-25. [https://www.nejm.org/doi/full/10.1056/NEJMoa1212299 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682658/ link to PMC article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1212299/suppl_file/nejmoa1212299_protocol.pdf supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23550669 PubMed]

==Goserelin monotherapy {{#subobject:9 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Goserelin (Zoladex) in prostate cancer]]
===Variant #1, 28-day cycles {{#subobject:9 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.goldjournal.net/article/0090-4295(91)80077-K/pdf Soloway et al. 1991 (Zoladex Prostate Study Group)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Castration|Bilateral orchiectomy]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/1828183 Kaisary et al. 1991]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Castration|Bilateral orchiectomy]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.sciencedirect.com/science/article/pii/S0022534717380801 Tyrrell et al. 1991 (IPCSG)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Flutamide_.26_Goserelin_2|Flutamide & Goserelin]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(05)80293-X/abstract Boccardo et al. 1993 (PONCAP)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Flutamide_.26_Goserelin_2|Flutamide & Goserelin]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Hormonotherapy====
*[[Goserelin (Zoladex)]] 3.6 mg SC once every 4 weeks

'''Continued indefinitely'''

===Variant #2, 84-day cycles {{#subobject:7afffe |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989846/ Ozono et al. 2018 (3550-CL-0010)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Degarelix_monotherapy|Degarelix]]
|style="background-color:#eeee01"|Non-inferior testosterone suppression
|-
|}
====Hormonotherapy====
*[[Goserelin (Zoladex)]] 3.6 mg SC once, then after 28 days, 10.8 mg SC once every 84 days

'''Continued indefinitely'''

===References===
# '''Zoladex Prostate Study Group:''' Soloway MS, Chodak G, Vogelzang NJ, Block NL, Schellhammer PF, Smith JA Jr, Scott M, Kennealey G, Gau TC; Zoladex Prostate Study Group. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Urology. 1991 Jan;37(1):46-51. [https://www.goldjournal.net/article/0090-4295(91)80077-K/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1824732 PubMed]
## '''Update:''' Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA Jr, Caplan RJ, Kennealey GT; Zoladex Prostate Study Group. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology. 1995 Aug;46(2):220-6. [http://www.goldjournal.net/article/S0090-4295(99)80197-6/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7624991 PubMed]
# Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991 May;67(5):502-8. [https://www.ncbi.nlm.nih.gov/pubmed/1828183 PubMed]
# '''IPCSG:''' Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F, Holdaway IM, Haefliger JM, Jordaan JP; The International Prostate Cancer Study Group. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol. 1991 Nov;146(5):1321-6. [https://www.sciencedirect.com/science/article/pii/S0022534717380801 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/1834864 PubMed] 
# '''PONCAP:''' Boccardo F, Pace M, Rubagotti A, Guarneri D, Decensi A, Oneto F, Martorana G, Giuliani L, Selvaggi F, Battaglia M, Delli Ponti U, Petracco S, Cortellini P, Ziveri M, Ferraris V, Bruttini GP, Epis R, Comeri G, Gallo G; The Italian Prostatic Cancer Project (PONCAP) Study Group. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur J Cancer. 1993;29A(8):1088-93. [https://www.ejcancer.com/article/S0959-8049(05)80293-X/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8518017 PubMed]
# '''3550-CL-0010:''' Ozono S, Tsukamoto T, Naito S, Horie S, Ohashi Y, Uemura H, Yokomizo Y, Fukasawa S, Kusuoka H, Akazawa R, Saito M, Akaza H. Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: a phase III study. Cancer Sci. 2018 Jun;109(6):1920-1929. Epub 2018 May 23. [https://onlinelibrary.wiley.com/doi/abs/10.1111/cas.13600 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989846/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29624800 PubMed]

==Intermittent ADT==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
IHT: '''<u>I</u>'''ntermittent '''<u>H</u>'''ormone '''<u>T</u>'''herapy
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.europeanurology.com/article/S0302-2838(09)00159-6/fulltext Calais da Silva et al. 2009]
|style="background-color:#1a9851"|Phase III (E)
|Continuous ADT
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521033/ Crook et al. 2012 (NCIC CTG PR.7)]
| style="background-color:#1a9851" |Phase III (E)
|Continuous ADT
| style="background-color:#eeee01" |Non-inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682658/ Hussain et al. 2013 (SWOG-9346)]
|style="background-color:#1a9851"|Phase III (E)
|Continuous ADT
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|[https://www.europeanurology.com/article/S0302-2838(13)00342-4/fulltext Calais da Silva et al. 2013]
|style="background-color:#1a9851"|Phase III (E)
|Continuous ADT
| style="background-color:#eeee01" |Non-inferior OS
|-
|}
''See papers for details about treatment holidays.''
====Hormonotherapy====
*[[:Category:GnRH agonists|LHRH agonist]]
*[[:Category:Nonsteroidal_antiandrogens|Nonsteroidal antiandrogen]] for at least 4 weeks

'''8-month cycles'''
===References===
# Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009 Jun;55(6):1269-77. Epub 2009 Feb 21. [https://www.europeanurology.com/article/S0302-2838(09)00159-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19249153 PubMed]
# '''NCIC CTG PR.7:''' Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012 Sep 6;367(10):895-903. Erratum in: N Engl J Med. 2012 Dec 6;367(23):2262. [https://www.nejm.org/doi/full/10.1056/NEJMoa1201546 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521033/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22931259 PubMed]
# '''SWOG-9346:''' Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4;368(14):1314-25. [https://www.nejm.org/doi/full/10.1056/NEJMoa1212299 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682658/ link to PMC article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1212299/suppl_file/nejmoa1212299_protocol.pdf supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23550669 PubMed]
# Calais da Silva F, Calais da Silva FM, Gon√ßalves F, Santos A, Kliment J, Whelan P, Oliver T, Antoniou N, Pastidis S, Marques Queimadelos A, Robertson C. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Eur Urol. 2014 Aug;66(2):232-9. Epub 2013 Apr 4. [https://www.europeanurology.com/article/S0302-2838(13)00342-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23582949 PubMed]

==Leuprolide monotherapy {{#subobject:12 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Leuprolide (Lupron) in prostate cancer]]
===Variant #1, daily {{#subobject:c6f258 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198411153112004 Garnick et al. 1984]
|style="background-color:#1a9851"|Phase III (E)
|Diethylstilbestrol
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#1a9850" |Less toxic
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198908173210702 Crawford et al. 1989 (SWOG-8494)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Flutamide_.26_Leuprolide|Flutamide & Leuprolide]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|
|-
|}
''Note: this is of historic importance only, given the wide availability of depot formulations of leuoprolide.''
====Hormonotherapy====
*[[Leuprolide (Lupron)]] 1 mg SC once per day

'''Continued indefinitely'''

===Variant #2, 1-month depot, 3.75 mg {{#subobject:172cb3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jjco.oxfordjournals.org/content/34/1/20.full Akaza et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|1. [[#Bicalutamide_.26_Goserelin_2|Bicalutamide & Goserelin]]<br> 2. [[#Bicalutamide_.26_Leuprolide|Bicalutamide & Leuprolide]]
|style="background-color:#fc8d59"|Seems to have inferior OS (*)
|-
|}
''Note: efficacy is based on the 2009 update.''
====Hormonotherapy====
*[[Leuprolide (Lupron)|Leuprolide (Lupron) 1-month depot]] 3.75 mg SC once on day 1

'''28-day cycles'''

===Variant #3, 1-month depot, 7.5 mg {{#subobject:172cb4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2008.08183.x/full Klotz et al. 2008 (CS21)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Degarelix_monotherapy|Degarelix 240/80]]
|style="background-color:#eeee01"|Non-inferior testosterone suppression
|-
|2. [[#Degarelix_monotherapy|Degarelix 240/160]]
|style="background-color:#eeee01"|Non-inferior testosterone suppression
|-
|}
====Hormonotherapy====
*[[Leuprolide (Lupron)|Leuprolide (Lupron) 1-month depot]] 7.5 mg IM once on day 1

'''28-day cycles'''
===Variant #4, 3-month depot {{#subobject:5415fc |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.clinicaltherapeutics.com/article/S0149-2918(96)80215-3/pdf Sharifi et al. 1996]
|style="background-color:#91cf61"|Phase II
|-
|}
====Hormonotherapy====
*[[Leuprolide (Lupron)|Leuprolide (Lupron) 3-month depot]] 22.5 mg IM once on day 1

'''84-day cycles'''

===Variant #5, 4-month depot {{#subobject:21b60f |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.goldjournal.net/article/S0090-4295(97)00500-1/pdf Sharifi et al. 1998]
|style="background-color:#91cf61"|Phase II
|-
|}
====Hormonotherapy====
*[[Leuprolide (Lupron)|Leuprolide (Lupron) 4-month depot]] 30 mg IM once on day 1

'''16-week cycles'''

===Other {{#subobject:12 |Variant=1}}===
*One of the following:
**[[Leuprolide (Lupron)|Leuprolide (Lupron) 6-month depot]] 45 mg IM once every 24 weeks
**[[Leuprolide (Lupron)|Leuprolide (Lupron) 4-month depot]] 30 mg IM once every 16 weeks
**[[Leuprolide (Lupron)|Leuprolide (Lupron) 3-month depot]] 22.5 mg IM once every 12 weeks
**[[Leuprolide (Lupron)|Leuprolide (Lupron) 1-month depot]] 7.5 mg IM once every 4 weeks

====Supportive medications====
*(varies depending on reference):
*[[Bicalutamide (Casodex)]] 50 mg PO once per day for protection from testosterone flare

'''Continued indefinitely'''
===References===
# Garnick MB, Glode LM; Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984 Nov 15;311(20):1281-6. [https://www.nejm.org/doi/full/10.1056/NEJM198411153112004 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/6436700 PubMed]
# '''SWOG-8494:''' Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419-24. Erratum in: N Engl J Med 1989 Nov 16;321(20):1420. [https://www.nejm.org/doi/full/10.1056/NEJM198908173210702 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2503724 PubMed]
# Sharifi R, Bruskewitz RC, Gittleman MC, Graham SD Jr, Hudson PB, Stein B. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther. 1996 Jul-Aug;18(4):647-57. [http://www.clinicaltherapeutics.com/article/S0149-2918(96)80215-3/pdf link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8879893 PubMed]
# Sharifi R, Knoll LD, Smith J, Kramolowsky E. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology. 1998 Feb;51(2):271-6. [http://www.goldjournal.net/article/S0090-4295(97)00500-1/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9495710 PubMed]
# Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda A, Arai Y, Usami M, Naito S, Kanetake H, Ohashi Y. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol. 2004 Jan;34(1):20-8. [http://jjco.oxfordjournals.org/content/34/1/20.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15020659 PubMed]
## '''Update:''' Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y; Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009 Aug 1;115(15):3437-45. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.24395 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19536889 PubMed]
# '''CS21:''' Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schr√∂der FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8. [https://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2008.08183.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19035858 PubMed]
## '''Update:''' Tombal B, Miller K, Boccon-Gibod L, Schr√∂der F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010 May;57(5):836-42. Epub 2009 Nov 20. [http://www.europeanurology.com/article/S0302-2838%2809%2901171-3 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19962227 PubMed]

==Nilutamide & Orchiectomy {{#subobject:15 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:15 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.sciencedirect.com/science/article/pii/S0022534717360032 Janknegt et al. 1993 (International Anandron Study Group)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Castration|Bilateral orchiectomy]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Nilutamide to start the day of, or day after surgical castration/orchiectomy.''
====Hormonotherapy====
*[[Nilutamide (Nilandron)]] 300 mg PO once per day x 1 month, then 150 mg PO once per day
*[[Endocrine_ablation_surgery#Bilateral_orchiectomy|Bilateral orchiectomy]]

'''Continued indefinitely'''
===References===
# '''International Anandron Study Group:''' Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM, Dijkman GD, Frick J, Goedhals J, Kn√∂nagel H, Venner PM. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol. 1993 Jan;149(1):77-82. [https://www.sciencedirect.com/science/article/pii/S0022534717360032 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/7678043 PubMed]
## '''Update:''' Janknegt RA; Anandron International Study Group. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Cancer. 1993 Dec 15;72(12 Suppl):3874-7. [https://www.ncbi.nlm.nih.gov/pubmed/8252507 PubMed]
## '''Update:''' Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM; International Anandron Study Group. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol. 1997 Jul;158(1):160-3. [https://www.ncbi.nlm.nih.gov/pubmed/9186345 PubMed]
## '''Update:''' de Reijke T, Derobert E; Anandron /Nilutamide Study Group. Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. Eur Urol. 2002 Aug;42(2):139-46. [http://www.europeanurology.com/article/S0302-2838%2802%2900272-5 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12160584 PubMed]

=Metastatic disease, second-line hormonal therapy=
==Abiraterone & Prednisone {{#subobject:16 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:16 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Overall response rate|'''ORR''', PSA RR]]
!Comparator [[Overall response rate|'''ORR''', PSA RR]]
!Pt Population
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471149/ de Bono et al. 2011 (COU-AA-301)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Prednisone_monotherapy|Prednisone]]
|style="background-color:#1a9850"|Superior OS
|14% (95% CI n/a), 29%
|3% (95% CI n/a), 6%
|Chemo-exposed
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683570/ Ryan et al. 2013 (COU-AA-302)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Prednisone_monotherapy|Prednisone]]
|style="background-color:#91cf60"|Seems to have superior OS
|36% (95% CI n/a), 62%
|16% (95% CI n/a), 24%
|Chemo-naive
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.77.9827 Attard et al. 2018 (PLATO)]
|style="background-color:#1a9851"|Phase III (C)
|Abiraterone, Enzalutamide, Prednisone
| style="background-color:#ffffbf" |Seems not superior
|
|
|Chemo-naive
|-
|}
====Preceding treatment====
*PLATO: [[#Enzalutamide_monotherapy_2|Enzalutamide]], with rising PSA
====Hormonotherapy====
*[[Abiraterone (Zytiga)]] 1000 mg PO once per day, 1 hour before or 2 hours after meals 
*[[Prednisone (Sterapred)]] 5 mg PO twice per day

'''Continued indefinitely'''

===References===
# '''COU-AA-301:''' de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fl√©chon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. [https://www.nejm.org/doi/full/10.1056/NEJMoa1014618 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471149/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21612468 PubMed]
## '''Update:''' Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct;13(10):983-92. Epub 2012 Sep 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70379-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22995653 PubMed]
## '''Update:''' Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012 Dec;13(12):1210-7. Epub 2012 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70473-4/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23142059 PubMed]
# '''COU-AA-302:''' Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. Epub 2012 Dec 10. [https://www.nejm.org/doi/full/10.1056/NEJMoa1209096 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683570/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23228172 PubMed]
## '''Update:''' Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152-60. Epub 2015 Jan 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71205-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25601341 PubMed]
# '''PLATO:''' Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R, Pham T, Taplin ME; PLATO collaborators. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol. 2018 Sep 1;36(25):2639-2646. Epub 2018 Jul 20. [http://ascopubs.org/doi/full/10.1200/JCO.2018.77.9827 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30028657 PubMed]

==Antiandrogen withdrawal {{#subobject:17 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:17 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/6/1025.long Small et al. 2004 (CALGB 9583)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Ketoconazole_.26_Hydrocortisone|Ketoconazole & Hydrocortisone]]
|style="background-color:#d73027"|Inferior PSA response
|-
|}

''Refers to cessation of antiandrogen therapy.''

===References===
# '''CALGB 9583:''' Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 Mar 15;22(6):1025-33. [http://jco.ascopubs.org/content/22/6/1025.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15020604 PubMed]

==Bicalutamide monotherapy {{#subobject:abb40a |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:cf9def|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Overall response rate|'''ORR''', PSA RR]]
!Comparator [[Overall response rate|'''ORR''', PSA RR]]
!Pt Population
|-
|[http://jco.ascopubs.org/content/34/18/2098.full Penson et al. 2016 (STRIVE)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Enzalutamide_monotherapy_2|Enzalutamide]]
|style="background-color:#d73027"|Inferior PFS
|pts w/ measurable disease: '''14%''' (95% CI n/a), '''31%''' (95% CI n/a)
|pts w/ measurable disease: '''60%''' (95% CI n/a), '''81%''' (95% CI n/a)
|Chemo-naive, abi and keto-naive
|-
|}
''Patients continued ADT while on study; details not provided.''
====Hormonotherapy====
*[[Bicalutamide (Casodex)]] 50 mg PO once per day

'''Continued indefinitely'''

===References===
<!-- Presented in part at the American Urological Association 2015 Annual Meeting, New Orleans, LA, May 15-19, 2015. -->
# '''STRIVE:''' Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol. 2016 Jun 20;34(18):2098-106. Epub 2016 Jan 25. [http://jco.ascopubs.org/content/34/18/2098.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26811535 PubMed]

==Enzalutamide monotherapy {{#subobject:18 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 160 mg/day {{#subobject:18 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Efficacy|Efficacy]], PSA RR
!Comparator [[Overall response rate|'''ORR''']], PSA RR
!Pt Population
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1207506 Scher et al. 2012 (AFFIRM)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Placebo|Placebo]]
|style="background-color:#1a9850"|Superior OS
|29% (95% CI n/a), 54%
|4% (95% CI n/a), 2%
|Chemo-exposed (docetaxel)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418931/ Beer et al. 2014 (PREVAIL)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Placebo|Placebo]]
|style="background-color:#1a9850"|Superior OS
|59% (95% CI n/a), 78%
|5% (95% CI n/a), 3%
|Chemo and abiraterone naive
|-
|[http://jco.ascopubs.org/content/34/18/2098.full Penson et al. 2016 (STRIVE)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Bicalutamide_monotherapy_2|Bicalutamide]]
|style="background-color:#1a9850"|Superior PFS
|60% (95% CI n/a), 81%
|14% (95% CI n/a), 31%
|Chemo and bicalutamide naive
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.77.9827 Attard et al. 2018 (PLATO)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|Chemo-naive
|-
|}
''Patients in STRIVE & PLATO continued ADT while on study or had a history of bilateral orchiectomy; details not provided.''
====Hormonotherapy====
*[[Enzalutamide (Xtandi)]] 160 mg PO once per day

'''Continued indefinitely'''
====Subsequent treatment====
*PLATO, with rising PSA: [[#Abiraterone_.26_Prednisone|Abiraterone & Prednisone]] versus Abiraterone, Enzalutamide, Prednisone

===Variant #2, 240 mg/day {{#subobject:7bf35b |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948179/ Scher et al. 2010 (S-3100-1-01)]
| style="background-color:#91cf61" |Phase I/II
|-
|}
''Note: this is the reported MTD from the phase I portion of the trial; however, it is NOT the dose used in subsequent phase III studies.''
====Hormonotherapy====
*[[Enzalutamide (Xtandi)]] 240 mg PO once per day

'''Continued indefinitely'''
===References===
# '''S-3100-1-01:''' Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24;375(9724):1437-46. Epub 2010 Apr 14. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60172-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948179/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20398925 PubMed]
# '''AFFIRM:''' Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl√©chon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15. [https://www.nejm.org/doi/full/10.1056/NEJMoa1207506 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22894553 PubMed]
<!-- # Beer TM, Armstrong AJ, Sternberg CN, Higano CS, Iversen P, Loriot Y, et al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. ASCO Meeting Abstracts. 2014 February 5, 2014;32(4_suppl):LBA1. [http://abstracts.asco.org/142/AbstView_142_123836.html link to original article] '''contains verified protocol''' -->
# '''PREVAIL:''' Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424-33. Epub 2014 Jun 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1405095 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418931/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24881730 PubMed]
## '''Update:''' Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B. Enzalutamide in men with chemotherapy-na√Øve metastatic castration-resistant prostate cancer: Extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017 Feb;71(2):151-154. Epub 2016 Jul 28. [http://www.europeanurology.com/article/S0302-2838(16)30437-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570461/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27477525 PubMed]
## '''HRQoL analysis:''' Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer TM, Tombal B, Loriot Y, Ivanescu C, Parli T, Balk M, Holmstrom S. Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health Qual Life Outcomes. 2017 Jun 23;15(1):130. [https://hqlo.biomedcentral.com/articles/10.1186/s12955-017-0704-y link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481866/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28645287 PubMed]
<!-- Presented in part at the American Urological Association 2015 Annual Meeting, New Orleans, LA, May 15-19, 2015. -->
# '''STRIVE:''' Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial. J Clin Oncol. 2016 Jun 20;34(18):2098-106. Epub 2016 Jan 25. [http://jco.ascopubs.org/content/34/18/2098.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26811535 PubMed]
# '''PLATO:''' Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R, Pham T, Taplin ME; PLATO collaborators. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol. 2018 Sep 1;36(25):2639-2646. Epub 2018 Jul 20. [http://ascopubs.org/doi/full/10.1200/JCO.2018.77.9827 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30028657 PubMed]

==Hydrocortisone monotherapy {{#subobject:f48fb4 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:da4be9 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.8.2506 Kantoff et al. 1999 (CALGB 9182)]
|style="background-color:#1a9851"|Phase III (C)
|Mitoxantrone & Hydrocortisone
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.7.1440 Small et al. 2000]
|style="background-color:#1a9851"|Phase III (C)
|Suramin & Hydrocortisone
| style="background-color:#d73027" |Inferior TTP
|-
|[https://academic.oup.com/annonc/article/15/11/1613/205647 Abratt et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|Vinorelbine & Hydrocortisone
| style="background-color:#fee08b" |Might have inferior PFS
|-
|}
====Hormonotherapy====
*[[Hydrocortisone (Cortef)]] 40 mg/day PO

'''Continued indefinitely'''

===References===
# '''CALGB 9182:''' Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999 Aug;17(8):2506-13. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.8.2506 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10561316 PubMed]
# Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000 Apr;18(7):1440-50. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.7.1440 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10735891 PubMed]
# Abratt RP, Brune D, Dimopoulos MA, Kliment J, Breza J, Selvaggi FP, Beuzeboc P, Demkow T, Oudard S. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol. 2004 Nov;15(11):1613-21. [https://academic.oup.com/annonc/article/15/11/1613/205647 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15520061 PubMed]

==Ketoconazole & Hydrocortisone {{#subobject:19 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:19 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Overall response rate|'''ORR''', PSA RR]]
!Comparator [[Overall response rate|'''ORR''', PSA RR]]
!Pt Population
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(84)92909-X/fulltext Trachtenberg & Pont 1984]
| style="background-color:#ffffbe" |Pilot
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|
|
|
|-
|[http://jco.ascopubs.org/content/22/6/1025.long Small et al. 2004 (CALGB 9583)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Antiandrogen_withdrawal|Antiandrogen withdrawal]]
|style="background-color:#1a9850"|Superior PSA response
|pts w/ measurable disease: '''20%''' (95% CI 11 - 32), '''27%''' (95% CI 20 - 35)
|pts w/ measurable disease: '''2%''' (95% CI 0 - 11), '''11%''' (95% CI 7 - 17)
|Progression at ADT, i.e. CRPC
|-
|}
====Hormonotherapy====
*[[Ketoconazole (Nizoral)]] 400 mg PO three times per day
*[[Hydrocortisone (Cortef)]] 30 mg PO QAM and 10 mg PO QPM

'''Continued indefinitely'''

===References===
# Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet. 1984 Aug 25;2(8400):433-5. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(84)92909-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6147504 PubMed]
# '''CALGB 9583:''' Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 Mar 15;22(6):1025-33. [http://jco.ascopubs.org/content/22/6/1025.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15020604 PubMed]

==Ketoconazole, Hydrocortisone, Dutasteride {{#subobject:20 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:20 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644858/ Taplin et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|}
====Hormonotherapy====
*[[Ketoconazole (Nizoral)]] 400 mg PO three times per day
*[[Hydrocortisone (Cortef)]] 30 mg PO QAM and 10 mg PO QPM
*[[Dutasteride (Avodart)]] 0.5 mg PO once per day

'''Continued indefinitely'''

===References===
# Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15;15(22):7099-105. Epub 2009 Nov 3. [http://clincancerres.aacrjournals.org/content/15/22/7099.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644858/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19887483 PubMed]

==Prednisone monotherapy {{#subobject:22 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 5 mg twice per day {{#subobject:22 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/jco.1989.7.5.590 Tannock et al. 1989]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1996.14.6.1756 Tannock et al. 1996]
|style="background-color:#1a9851"|Phase III (C)
|[[#Mitoxantrone_.26_Prednisone|Mitoxantrone & Prednisone]]
|style="background-color:#d73027"|Inferior palliation
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.20.1228 Sternberg et al. 2009 (SPARC)]
|style="background-color:#1a9851"|Phase III (C)
|Satraplatin & Prednisone
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471149/ de Bono et al. 2011 (COU-AA-301)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Abiraterone_.26_Prednisone|Abiraterone & Prednisone]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683570/ Ryan et al. 2013 (COU-AA-302)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Abiraterone_.26_Prednisone|Abiraterone & Prednisone]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70027-6/fulltext Saad et al. 2015 (ELM-PC 4)]
|style="background-color:#1a9851"|Phase III (C)
|Orteronel & Prednisone
| style="background-color:#d73027" |Inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.65.5597 Smith et al. 2016 (COMET-1)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cabozantinib_monotherapy|Cabozantinib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Hormonotherapy====
*[[Prednisone (Sterapred)]] 5 mg PO twice per day

'''Continued indefinitely'''

===Variant #2, 5 mg QID {{#subobject:5055a7 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.1.62 Foss√• et al. 2001 (EORTC 30903)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Flutamide_monotherapy|Flutamide]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Hormonotherapy====
*[[Prednisone (Sterapred)]] 5 mg PO QID (4 times per day)

'''Continued indefinitely'''

===References===
# Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989 May;7(5):590-7. [http://ascopubs.org/doi/10.1200/jco.1989.7.5.590 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2709088 PubMed]
# Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996 Jun;14(6):1756-64. [http://ascopubs.org/doi/full/10.1200/JCO.1996.14.6.1756 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8656243 PubMed]
## '''HRQoL analysis:''' Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999 Jun;17(6):1654-63. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.6.1654 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10561201 PubMed]
# '''EORTC 30903:''' Foss√• SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, Aaronson N, de Prijck L, Collette L. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001 Jan 1;19(1):62-71. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.1.62 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11134196 PubMed]
# '''SPARC:''' Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabr√≤ F, James N, Bodrogi I, Harper P, Wirth M, Berry W, Petrone ME, McKearn TJ, Noursalehi M, George M, Rozencweig M. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009 Nov 10;27(32):5431-8. Epub 2009 Oct 5. [http://ascopubs.org/doi/full/10.1200/JCO.2008.20.1228 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19805692 PubMed]
# '''COU-AA-301:''' de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fl√©chon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. [https://www.nejm.org/doi/full/10.1056/NEJMoa1014618 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471149/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21612468 PubMed]
## '''Update:''' Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct;13(10):983-92. Epub 2012 Sep 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70379-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22995653 PubMed]
## '''Update:''' Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012 Dec;13(12):1210-7. Epub 2012 Nov 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70473-4/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23142059 PubMed]
# '''COU-AA-302:''' Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. Epub 2012 Dec 10. [https://www.nejm.org/doi/full/10.1056/NEJMoa1209096 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683570/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23228172 PubMed]
## '''Update:''' Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152-60. Epub 2015 Jan 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71205-7/fulltext link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/25601341 PubMed]
# '''ELM-PC 4:''' Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015 Mar;16(3):338-48. Epub 2015 Feb 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70027-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25701170 PubMed]
# '''COMET-1:''' Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, B√∂gemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Hou√©d√© N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016 Sep 1;34(25):3005-13. Epub 2016 Jul 11. [http://ascopubs.org/doi/full/10.1200/JCO.2015.65.5597 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27400947 PubMed]

=Chemotherapy for metastatic castrate-resistant disease=
==Cabazitaxel & Prednisone {{#subobject:23 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Cabazitaxel (Jevtana) in prostate cancer]]

===Variant #1, 20 mg/m<sup>2</sup> {{#subobject:fa59fa |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan = "2"|[http://ascopubs.org/doi/full/10.1200/JCO.2016.72.1068 Oudard et al. 2017 (FIRSTANA)]
|rowspan = "2" style="background-color:#1a9851"|Phase III (E)
|Cabazitaxel 25 mg/m<sup>2</sup> & Prednisone
|style="background-color:#ffffbf"|Seems not superior
|-
|[[#Docetaxel_.26_Prednisone|Docetaxel & Prednisone]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.72.1076 Eisenberger et al. 2017 (PROSELICA)]
|style="background-color:#1a9851"|Phase III (E)
|Cabazitaxel 25 mg/m<sup>2</sup> & Prednisone
|style="background-color:#eeee01"|Non-inferior OS
|-
|}
====Chemohormonotherapy====
*[[Cabazitaxel (Jevtana)]] 20 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 10 mg PO once per day

'''21-day cycles'''

===Variant #2, 25 mg/m<sup>2</sup> {{#subobject:23 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Overall response rate|'''ORR''', PSA RR]]
!Comparator [[Overall response rate|'''ORR''', PSA RR]]
!Pt Population
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext de Bono et al. 2010 (TROPIC)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Mitoxantrone_.26_Prednisone|Mitoxantrone & Prednisone]]
|style="background-color:#1a9850"|Superior OS
|14% (95% CI 10-19)<br> 39% (95% CI 34-44) (*)
|4% (95% CI 2-7)<br> 18% (95% CI 14-22) (*)
|Progressed on docetaxel
|-
|rowspan = "2"|[http://ascopubs.org/doi/full/10.1200/JCO.2016.72.1068 Oudard et al. 2017 (FIRSTANA)]
|rowspan = "2" style="background-color:#1a9851"|Phase III (E)
|Cabazitaxel 20 mg/m<sup>2</sup> & Prednisone
|style="background-color:#ffffbf"|Seems not superior
|
|
|
|-
|[[#Docetaxel_.26_Prednisone|Docetaxel & Prednisone]]
|style="background-color:#ffffbf"|Seems not superior
|
|
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.72.1076 Eisenberger et al. 2017 (PROSELICA)]
|style="background-color:#1a9851"|Phase III (C)
|Cabazitaxel 20 mg/m<sup>2</sup> & Prednisone
|style="background-color:#eeee01"|Non-inferior OS
|
|
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30605-8/fulltext Beer et al. 2017 (AFFINITY)]
|style="background-color:#1a9851"|Phase III (C)
|Cabazitaxel, Prednisone, Custirsen
|style="background-color:#ffffbf"|Seems not superior
|
|
|Progressed on docetaxel
|-
|}
''Note: ORRs in TROPIC were only reported for patients with measurable disease.''
====Chemohormonotherapy====
*[[Cabazitaxel (Jevtana)]] 25 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Prednisone (Sterapred)]] 10 mg PO once per day

====Supportive medications====
*[[:Category:Antihistamines|Antihistamine]] given at least 30 minutes before [[Cabazitaxel (Jevtana)]]
*[[:Category:Steroids|Corticosteroid]] ([[Dexamethasone (Decadron)|dexamethasone]] 8 mg or equivalent) given at least 30 minutes before [[Cabazitaxel (Jevtana)]]
*[[:Category:Antihistamines|Histamine H2-antagonist]] (except cimetidine) given at least 30 minutes before [[Cabazitaxel (Jevtana)]]

'''21-day cycle for up to 10 cycles (TROPIC) or indefinitely (PROSELICA)'''

===References===
# '''TROPIC:''' de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20888992 PubMed]
# '''FIRSTANA:''' Oudard S, Fizazi K, Sengel√∏v L, Daugaard G, Saad F, Hansen S, Hj√§lm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III Trial-FIRSTANA. J Clin Oncol. 2017 Oct 1;35(28):3189-3197. Epub 2017 Jul 28. [http://ascopubs.org/doi/full/10.1200/JCO.2016.72.1068 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28753384 PubMed]
# '''PROSELICA:''' Eisenberger M, Hardy-Bessard AC, Kim CS, G√©czi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m(2)) and the currently approved dose (25 mg/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol. 2017 Oct 1;35(28):3198-3206. Epub 2017 Aug 15 [http://ascopubs.org/doi/full/10.1200/JCO.2016.72.1076 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28809610 PubMed]
# '''AFFINITY:''' Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fl√©chon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1532-1542. Epub 2017 Oct 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30605-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29033099 PubMed]

==Cabozantinib monotherapy {{#subobject:a20f66 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 60 mg/day {{#subobject:0eb568 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.65.5597 Smith et al. 2016 (COMET-1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Prednisone_monotherapy|Prednisone]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cabozantinib (Cometriq)]] 60 mg PO once per day

===Variant #2, 100 mg/day {{#subobject:2efaa6 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110249/ Smith et al. 2012]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cabozantinib (Cometriq)]] 100 mg PO once per day

'''Continued indefinitely'''
===References===
# Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Sch√∂ffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 1;31(4):412-9. Epub 2012 Nov 19. [http://jco.ascopubs.org/content/31/4/412.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110249/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23169517 PubMed]
# '''COMET-1:''' Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, B√∂gemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Hou√©d√© N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016 Sep 1;34(25):3005-13. Epub 2016 Jul 11. [http://ascopubs.org/doi/full/10.1200/JCO.2015.65.5597 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27400947 PubMed]

==Carboplatin & Docetaxel {{#subobject:28 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Example orders===
*[[Example orders for Docetaxel & Carboplatin in prostate cancer]]

===Variant #1, 4/60 {{#subobject:31 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.23195/full Ross et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
''Patients enrolled in the trial had hormone-refractory prostate cancer and progression of disease during docetaxel treatment or within 45 days of stopping docetaxel treatment.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 4 (Calvert formula) IV over 60 minutes once on day 1, '''given second'''
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''

====Supportive medications====
*"Standard dexamethasone premedication was used"
*Patients continued to receive androgen deprivation therapy

'''21-day cycles'''

===Variant #2, 5/35, weekly docetaxel {{#subobject:32 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://link.springer.com/article/10.1007%2Fs00345-010-0527-5 Reuter et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
''Patients enrolled in the trial had progression of disease on docetaxel chemotherapy and castration-resistant disease.''
====Chemohormonotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 30 minutes once on day 1
*[[Docetaxel (Taxotere)]] 35 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15
**Note: In contrast to its abstract, Reuter et al. 2010 sometimes used "days 1, 8, (15)" to describe when docetaxel was given. The paper did not specifically say what "(15)" meant, such as whether this meant that the day 15 dose was optional.
*[[Prednisone (Sterapred)]] 5 mg PO twice per day on days 1 to 28

====Supportive medications====
*"Standard dexamethasone premedication was used"
*Patients continued to receive LHRH (luteinizing hormone releasing hormone) agonists
*No routine use of granulocyte colony-stimulating factor (G-CSF)

'''28-day cycles'''

===References===
# Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK; Prostate Cancer Clinical Trials Consortium. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008 Feb 1;112(3):521-6. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.23195/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18085595 PubMed]
# '''Retrospective:''' Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008 Feb;101(3):308-12. [https://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2007.07331.x/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18184327 PubMed]
# Reuter CW, Morgan MA, Ivanyi P, Fenner M, Ganser A, Gr√ºnwald V. Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. World J Urol. 2010 Jun;28(3):391-8. Epub 2010 Mar 14. [http://link.springer.com/article/10.1007%2Fs00345-010-0527-5 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20229232 PubMed]

==Carboplatin & Paclitaxel {{#subobject:30 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:34 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://link.springer.com/article/10.1007%2Fs00280-012-1896-9 Kentepozidis et al. 2012]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 3 (Calvert formula) IV once per day on days 1 & 15, '''given second'''
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 15, '''given first'''

====Supportive medications====
*"All patients received a concomitant anti-emetic prophylaxis"
*[[Dexamethasone (Decadron)]] 20 mg PO given twice, 12 and 6 hours prior to [[Paclitaxel (Taxol)]]
*[[Diphenhydramine (Benadryl)]] 50 mg IV once "prior to each dose" (there was nothing else after this in Kentepozidis et al. 2012, and it is assumed to mean prior to each dose of [[Paclitaxel (Taxol)]])
*[[Cimetidine (Tagamet)]] 300 mg IV once "prior to each dose" (there was nothing else after this in Kentepozidis et al. 2012, and it is assumed to mean prior to each dose of [[Paclitaxel (Taxol)]])
*No prophylactic G-CSF

'''28-day cycles'''

===Variant #2 {{#subobject:35 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.urologiconcology.org/article/S1078-1439%2810%2900003-7/abstract Jeske et al. 2010]
|style="background-color:#ffffbe"|Retrospective
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 4 to 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 60 to 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# '''Retrospective:''' Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM. Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. Urol Oncol. 2011 Nov-Dec;29(6):676-81. Epub 2010 May 7. [http://www.urologiconcology.org/article/S1078-1439%2810%2900003-7/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20451413 PubMed]
# Kentepozidis N, Soultati A, Giassas S, Vardakis N, Kalykaki A, Kotsakis A, Papadimitraki E, Pantazopoulos N, Bozionellou V, Georgoulias V. Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. Cancer Chemother Pharmacol. 2012 Jul;70(1):161-8. Epub 2012 Jun 3. [http://link.springer.com/article/10.1007%2Fs00280-012-1896-9 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22660737 PubMed]

==Cyclophosphamide, Prednisone, Diethylstilbestrol {{#subobject:26 |Regimen=1}}==
CPD: '''<u>C</u>'''yclophosphamide, '''<u>P</u>'''rednisone, '''<u>D</u>'''iethylstilbestrol

{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:26 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.11686/abstract Hellerstedt et al. 2003]
|style="background-color:#91cf61"|Phase II
|50% or greater decline in PSA: 42%
|-
|}
====Chemohormonotherapy====
*[[Cyclophosphamide (Cytoxan)]] 100 mg PO once per day on days 1 to 20
*[[Prednisone (Sterapred)]] 10 mg PO once per day on days 1 to 30
*[[Diethylstilbestrol (DES)]] 1 mg PO once per day on days 1 to 30

====Supportive medications====
*[[Warfarin (Coumadin)]] 1 mg PO once per day to decrease risk of DVT

'''30-day cycles'''

===References===
# Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, Olson K, Smith DC. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer. 2003 Oct 15;98(8):1603-10. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.11686/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14534875 PubMed]

==Docetaxel & Prednisone {{#subobject:27 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Docetaxel (Taxotere) in prostate cancer]]

===Variant #1, 30 mg/m<sup>2</sup> weekly {{#subobject:29 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa040720 Tannock et al. 2004 (TAX 327)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Every 3-week Docetaxel & Prednisone
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Mitoxantrone_.26_Prednisone|Mitoxantrone & Prednisone]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemohormonotherapy====
*[[Docetaxel (Taxotere)]] 30 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, 22, 29
*[[Prednisone (Sterapred)]] 5 mg PO twice per day

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg (route not specified) once 1 hour before [[Docetaxel (Taxotere)]]
*Antiemetics "according to local practice"

'''42-day cycle for up to 5 cycles'''

===Variant #2, 50 mg/m<sup>2</sup> bi-weekly {{#subobject:30 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2812%2970537-5/abstract Kellokumpu-Lehtinen et al. 2013 (PROSTY]
|style="background-color:#1a9851"|Phase III (E)
|Every 3-weeks Docetaxel & Prednisone
|style="background-color:#91cf60"|Seems to have superior TTTF
|-
|}
====Chemohormonotherapy====
*[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 15
*[[Prednisolone (Millipred)]] 10 mg PO once per day

====Supportive medications====
*[[Dexamethasone (Decadron)]] 7.5 to 8 mg (route not specified) once per day, started 1 day before [[Docetaxel (Taxotere)]] and stopped 1 to 2 days after docetaxel infusion (in other words, from day -1 to day 2 or 3)
*G-CSF not recommended unless patients developed febrile neutropenia or severe infection
*"Treatment with bisphosphonates, erythropoietin, and palliative radiation therapy was allowed"

'''28-day cycles'''

===Variant #3, 75 mg/m<sup>2</sup> q3wk, limited duration {{#subobject:27 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Overall response rate|'''ORR''', PSA RR]]
!Comparator [[Overall response rate|'''ORR''', PSA RR]]
!Pt Population
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa040720 Tannock et al. 2004 (TAX 327)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Weekly Docetaxel & Prednisone
|style="background-color:#d3d3d3"|Not reported
|rowspan=2|pts w/ measurable disease:'''12%''' (95% CI, 7-19), '''45%''' (95% CI, 40-51)
|pts w/ measurable disease:'''8%''' (95% CI, 4-14), '''48%''' (95% CI, 42-54)
|Chemo-naive
|-
|2. [[#Mitoxantrone_.26_Prednisone|Mitoxantrone & Prednisone]]
|style="background-color:#1a9850"|Superior OS
|pts w/ measurable disease:'''7%''' (95% CI, 3-12), '''32%''' (95% CI, 26-37)
|Chemo-naive
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.06.8197 Beer et al. 2011 (ASCENT)]
|style="background-color:#1a9851"|Phase III (C)
|Calcitriol, Docetaxel, Prednisone
|style="background-color:#1a9850"|Superior OS (*)
|
|
|
|-
|[https://www.ejcancer.com/article/S0959-8049(12)00428-5/fulltext Meulenbeld et al. 2012 (NePro)]
|style="background-color:#1a9851"|Phase II/III (C)
|Docetaxel, Prednisone, Risedronate
|style="background-color:#ffffbf"|Seems not superior
|
|
|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277263/ Quinn et al. 2013 (SWOG S0421)]
|style="background-color:#1a9851"|Phase III (C)
|Atrasentan, Docetaxel, Prednisone
|style="background-color:#ffffbf"|Seems not superior
|
|
|
|-
|}
''Note: reported efficacy for ASCENT is based on the 2011 update.''
====Chemohormonotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Prednisone (Sterapred)]] 5 mg PO twice per day

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO given three times; 12 hours, 3 hours, and 1 hour before [[Docetaxel (Taxotere)]]
*[[:Category:Emesis_prevention|Antiemetics]] "according to local practice"

'''21-day cycle for up to 10 cycles (TAX 327; ASCENT; NePro) or 12 cycles (SWOG S0421)'''

===Variant #4, 75 mg/m<sup>2</sup> q3wk, indefinite, with prednisone {{#subobject:ea941e |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383121/ Kelly et al. 2012 (CALGB 90401)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel, Prednisone, Bevacizumab
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.46.4149 Fizazi et al. 2013 (ENTHUSE)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel, Prednisone, Zibotentan
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70184-0/abstract Tannock et al. 2013 (VENICE)]
|style="background-color:#1a9851"|Phase III (C)
|Dasatinib, Docetaxel, Prednisone
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70479-0/abstract Araujo et al. 2013 (READY)]
|style="background-color:#1a9851"|Phase III (C)
|Dasatinib, Docetaxel, Prednisone
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70025-2/abstract Petrylak et al. 2015 (MAINSAIL)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel, Lenalidomide, Prednisone
|style="background-color:#1a9850"|Superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30168-7/fulltext Chi et al. 2017 (SYNERGY)]
|style="background-color:#1a9851"|Phase III (C)
|Custirsen, Docetaxel, Prednisone
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan = "2"|[http://ascopubs.org/doi/full/10.1200/JCO.2016.72.1068 Oudard et al. 2017 (FIRSTANA)]
|rowspan = "2" style="background-color:#1a9851"|Phase III (C)
|[[#Cabazitaxel_.26_Prednisone|Cabazitaxel 20 mg/m<sup>2</sup> & Prednisone]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[[#Cabazitaxel_.26_Prednisone|Cabazitaxel 25 mg/m<sup>2</sup> & Prednisone]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: CALGB 90401 discontinued treatment after a maximum of 2 years.''
====Chemohormonotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] as follows:
**CALGB 90401: 5 mg PO once per day
**Others: 10 mg/day; some regimens give as 5 mg PO twice per day, some as 10 mg PO once per day

'''21-day cycles'''

===Variant #5, 75 mg/m<sup>2</sup> q3wk, indefinite, with prednisolone {{#subobject:28 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2812%2970537-5/abstract Kellokumpu-Lehtinen et al. 2013 (PROSTY)]
|style="background-color:#1a9851"|Phase III (C)
|Every 2-weeks Docetaxel & Prednisone
|style="background-color:#fc8d59"|Seems to have inferior TTTF
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.46.4149 Fizazi et al. 2013 (ENTHUSE)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel, Prednisolone, Zibotentan
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemohormonotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Prednisolone (Millipred)]] 10 mg PO once per day
**Fizazi et al. 2013: Given as 5 mg PO twice per day

====Supportive medications====
*[[Dexamethasone (Decadron)]] 7.5 to 8 mg daily, started 1 day before [[Docetaxel (Taxotere)]] and stopped 1 to 2 days after docetaxel infusion (in other words, from day -1 to day 2 or 3); reference did not specify route of administration
*G-CSF not recommended unless patients developed febrile neutropenia or severe infection
*"Treatment with bisphosphonates, erythropoietin, and palliative radiation therapy was allowed"

'''21-day cycles'''

===References===
# '''TAX 327:''' Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Th√©odore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502-12. [https://www.nejm.org/doi/full/10.1056/NEJMoa040720 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15470213 PubMed]
## '''Update:''' Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008 Jan 10;26(2):242-5. [http://jco.ascopubs.org/content/26/2/242.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18182665 PubMed]
# '''ASCENT:''' Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007 Feb 20;25(6):669-74. [http://ascopubs.org/doi/full/10.1200/JCO.2006.06.8197 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17308271 PubMed]
## '''Update:''' Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011 Jun 1;29(16):2191-8. Epub 2011 Apr 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.32.8815 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21483004 PubMed]
<!-- Presented in part at the 48th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''CALGB 90401:''' Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012 May 1;30(13):1534-40. Epub 2012 Mar 26. [http://ascopubs.org/doi/full/10.1200/JCO.2011.39.4767 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383121/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22454414 PubMed]
# '''NePro:''' Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Foss√• SD, Polee M, Gerritsen W, Dalesio O, de Wit R. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). Eur J Cancer. 2012 Nov;48(16):2993-3000. Epub 2012 Jun 6. [https://www.ejcancer.com/article/S0959-8049(12)00428-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22677260 PubMed]
# '''PROSTY:''' Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H; for the PROSTY study group. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013 Feb;14(2):117-24. Epub 2013 Jan 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2812%2970537-5/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23294853 PubMed]
# '''ENTHUSE:''' Fizazi K, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013 May 10;31(14):1740-7. Epub 2013 Apr 8. Erratum in: J Clin Oncol. 2014 Oct 20;32(30):3461. Fizazi, Karim S [Corrected to Fizazi, Karim]. [http://ascopubs.org/doi/full/10.1200/JCO.2012.46.4149 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23569308 PubMed]
# '''VENICE:''' Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fl√©chon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Ar√©n O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; VENICE investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013 Jul;14(8):760-8. Epub 2013 Jun 4.[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70184-0/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23742877 PubMed]
# '''SWOG S0421:''' Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug;14(9):893-900. Epub 2013 Jul 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70294-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277263/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23871417 PubMed]
# '''READY:''' Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec;14(13):1307-16. Epub 2013 Nov 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70479-0/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478530/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24211163 PubMed]
# '''MAINSAIL:''' Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015 Apr;16(4):417-25. Epub 2015 Mar 3.[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70025-2/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25743937 PubMed]
# '''SYNERGY:''' Chi KN, Higano CS, Blumenstein B, Ferrero JM, Reeves J, Feyerabend S, Gravis G, Merseburger AS, Stenzl A, Bergman AM, Mukherjee SD, Zalewski P, Saad F, Jacobs C, Gleave M, de Bono JS. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2017 Apr;18(4):473-485. Epub 2017 Mar 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30168-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28283282 PubMed]
# '''FIRSTANA:''' Oudard S, Fizazi K, Sengel√∏v L, Daugaard G, Saad F, Hansen S, Hj√§lm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III Trial-FIRSTANA. J Clin Oncol. 2017 Oct 1;35(28):3189-3197. Epub 2017 Jul 28. [http://ascopubs.org/doi/full/10.1200/JCO.2016.72.1068 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28753384 PubMed]

==Mitoxantrone & Prednisone {{#subobject:29 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Mitoxantrone (Novantrone) in prostate cancer]]

===Regimen {{#subobject:33 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
![[Overall response rate|'''ORR''', PSA RR]]
!Comparator [[Overall response rate|'''ORR''', PSA RR]]
!Pt Population
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1996.14.6.1756 Tannock et al. 1996]
|style="background-color:#1a9851"|Phase III (E)
|[[#Prednisone_monotherapy|Prednisone]]
|style="background-color:#1a9850" |Superior palliation
|
|
|
|-
|[https://jurology.com/retrieve/pii/S0022534705641638 Berry et al. 2002]
|style="background-color:#1a9851"|Phase III (E)
|[[#Prednisone_monotherapy|Prednisone]]
| style="background-color:#91cf60" |Seems to have superior TTTF
|
|
|
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa040720 Tannock et al. 2004 (TAX 327)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Docetaxel_.26_Prednisone|Weekly Docetaxel & Prednisone]]
|style="background-color:#ffffbf"|Seems not superior
|rowspan=2|pts w/ measurable disease: '''7%''' (95% CI 3-12), '''32%''' (95% CI 26-37)
|pts w/ measurable disease: '''8%''' (95% CI 4-14), '''48%''' (95% CI 42-54)
|Chemo naive
|-
|2. [[#Docetaxel_.26_Prednisone|Every 3-week Docetaxel & Prednisone]]
|style="background-color:#d73027"|Inferior OS
|pts w/ measurable disease: '''12%''' (95% CI 7-19), '''45%''' (95% CI 40-51)
|Chemo naive
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa041318 Petrylak et al. 2004 (SWOG S9916)]
|style="background-color:#1a9851"|Phase III (C)
|Docetaxel & Estramustine
|style="background-color:#fc8d59"|Seems to have inferior OS
|
|
|
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext de Bono et al. 2010 (TROPIC)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cabazitaxel_.26_Prednisone|Cabazitaxel & Prednisone]]
|style="background-color:#d73027"|Inferior OS
|pts w/ measurable disease:<br>'''4.4%''' (95% CI 1.6 - 7.2), '''17.8%''' (95% CI 13.7 - 22.0)
|pts w/ measurable disease:<br>'''14.4%''' (95% CI 9.6 - 19.3), '''39.2%''' (95% CI 33.9 - 44.5)
|Progressed on docetaxel
|-
|}
====Chemohormonotherapy====
*[[Mitoxantrone (Novantrone)]] 12 mg/m<sup>2</sup> IV over 15 to 30 minutes once on day 1
*[[Prednisone (Sterapred)]] 10 mg PO once per day on days 1 to 21
**Some protocols give 5 mg PO twice per day

'''21-day cycle for up to 10 cycles'''

===References===
# Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996 Jun;14(6):1756-64. [http://ascopubs.org/doi/full/10.1200/JCO.1996.14.6.1756 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8656243 PubMed]
## '''HRQoL analysis:''' Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999 Jun;17(6):1654-63. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.6.1654 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10561201 PubMed]
# Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002 Dec;168(6):2439-43. [https://jurology.com/retrieve/pii/S0022534705641638 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12441935 PubMed]
# '''TAX 327:''' Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Th√©odore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502-12. [https://www.nejm.org/doi/full/10.1056/NEJMoa040720 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15470213 PubMed]
## '''Update:''' Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008 Jan 10;26(2):242-5. [http://jco.ascopubs.org/content/26/2/242.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18182665 PubMed]
# '''SWOG S9916:''' Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1513-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa041318 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15470214 PubMed]
# '''TROPIC:''' de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20888992 PubMed]

==Olaparib monotherapy {{#subobject:defe72|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8979a3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/33/3/244.long Kaufman et al. 2014]
|style="background-color:#ffffbe"|Phase II, <20 pts in subgroup
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228595/ Mateo et al. 2015 (TOPARP-A)]
|style="background-color:#91cf61"|Phase II
|-
|}
*''Patients in Kaufman et al. 2014 had germline BRCA1/2 mutations and had progression on hormonal and one systemic therapy.''
*''Patients in Mateo et al. 2015 (TOPARP-A) who were found to have homozygous deletions, deleterious mutations, or both in DNA-repair genes were much more likely to respond to olaparib.''

====Chemotherapy====
*[[Olaparib (Lynparza)]] 400 mg PO twice per day

'''Continued indefinitely'''

===References===
<!-- Presented at the 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 4, 2013. -->
# Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balma√±a J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. [http://jco.ascopubs.org/content/33/3/244.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25366685 PubMed]
# '''TOPARP-A:''' Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015 Oct 29;373(18):1697-708. [https://www.nejm.org/doi/full/10.1056/NEJMoa1506859Top link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228595/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26510020 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.22996 Carducci et al. 2007]
| style="background-color:#1a9851" |Phase III (C)
|Atrasentan
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.27674 Nelson et al. 2012]
| style="background-color:#1a9851" |Phase III (C)
|Zibotentan
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No active antineoplastic therapy.''
===References===
# Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB; Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007 Nov 1;110(9):1959-66. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.22996 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17886253 PubMed]
# Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer. 2012 Nov 15;118(22):5709-18. Epub 2012 Jul 11. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.27674 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22786751 PubMed]

=Immunotherapy for metastatic castrate-resistant disease=

==Ipilimumab & RT {{#subobject:33 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy

===Regimen {{#subobject:38 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 25%"|Patient population
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707423/ Slovin et al. 2013]
|style="background-color:#91cf61"|Phase I/II
|ORR: 4% (95% CI n/a), PSA RR: 16%; 
|Most had ADT, some had docetaxel use. 10 mg/kg cohort reported here.
|-
|}
====Immunoradiotherapy====
*[[Ipilimumab (Yervoy)]] 10 mg/kg IV over 90 minutes once on day 1
**Lower doses including 3 mg/kg (the FDA approved dose) were investigated, but the 10 mg/kg dose was recommended in this study
*[[External_beam_radiotherapy|Radiation therapy]] given focally at a single dose of 8 Gy per target bone lesion for up to three bone lesions per patient, '''given 24 to 48 h before the first ipilimumab dose'''

'''21-day cycle for 4 cycles'''

===References===
# Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013 Jul;24(7):1813-21. [http://annonc.oxfordjournals.org/content/24/7/1813.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707423/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23535954 PubMed]

==Sipuleucel-T monotherapy {{#subobject:32 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Sipuleucel-T (Provenge) in prostate cancer]]
===Regimen {{#subobject:37 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.04.5252 Small et al. 2006]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Placebo|Placebo]]
| style="background-color:#d9ef8b" |Might have superior TTP
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1001294 Kantoff et al. 2010 (IMPACT<sub>prostate</sub>)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Placebo|Placebo]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''Note: IMPACT should not be confused with the studies of the same name in breast cancer and colorectal cancer.''
====Immunotherapy====
*[[Sipuleucel-T (Provenge)]]: leukapheresis followed 3 days later with at least 50 million autologous CD54+ cells activated with PAP-GM-CSF, to be done on weeks 0, 2, and 4

====Supportive medications====
*[[Acetaminophen (Tylenol)]] PO once 30 minutes before each dose
*[[:Category:Antihistamines|Antihistamine]] PO once 30 minutes before each dose

'''One course'''
===References===
# Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1;24(19):3089-94. [http://ascopubs.org/doi/full/10.1200/JCO.2005.04.5252 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16809734 PubMed]
# '''IMPACT:''' Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411-22. [https://www.nejm.org/doi/full/10.1056/NEJMoa1001294 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20818862 PubMed]
# '''Safety analysis:''' Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol. 2011 Sep;186(3):877-81. Epub 2011 Jul 23. [http://www.jurology.com/article/S0022-5347(11)03851-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21788048 PubMed]

=Radioactive agents for bony metastatic disease=

==Radium-223 monotherapy {{#subobject:35 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:40 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1213755 Parker et al. 2013 (ALSYMPCA)]
|style="background-color:#1a9851"|Phase III (E)
|[[Prostate_cancer_-_historical#Placebo|Placebo]]
|style="background-color:#1a9850"|Superior OS
|style="background-color:#1a9850"|Superior EQ-5D score
|-
|}
====Radiotherapy====
*[[Radium-223 (Xofigo)]] 50 kBq/kg IV once on day 1

'''28-day cycle for 6 cycles'''

===Variant #2 {{#subobject:41 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(07)70147-X/abstract Nilsson et al. 2007]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[Prostate_cancer_-_historical#Placebo|Placebo]]
|style="background-color:#d9ef8b"|Might have superior OS
|-
|}
''Patients in the study had "bone pain needing EBRT" (external beam radiation therapy). Treatment with radium 223 began within 7 days after EBRT.''
====Radiotherapy====
*[[Radium-223 (Xofigo)]] 50 kBq/kg IV once on day 1

'''28-day cycle for 4 cycles'''

===References===
# Nilsson S, Franz√©n L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennern√§s B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007 Jul;8(7):587-94. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(07)70147-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17544845 PubMed]
## '''Update:''' Nilsson S, Franz√©n L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennern√§s B, Petersson U, Johannessen DC, Sokal M, Pigott K, O'Bryan-Tear CG, Thuresson M, Bolstad B, Bruland √òS. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer. 2013 Mar;11(1):20-6. Epub 2012 Sep 26. [http://www.clinical-genitourinary-cancer.com/article/S1558-7673(12)00168-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23021204 PubMed]
<!--
# Chris Parker, Sten Nilsson, Daniel Heinrich, Joe M. O'Sullivan, Sophie D. Fossa, Ales Chodacki, Pawel J. Wiechno, John P. Logue, Mihalj Seke, Anders Widmark, Dag Clement Johannessen, Peter Hoskin, David Bottomley, Robert Edward Coleman, Nicholas J. Vogelzang, C. Gillies O'Bryan-Tear, Jose E. Garcia-Vargas, Minghua Shan, A. Oliver Sartor. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). 2012 ASCO Annual Meeting Abstract LBA4512. [http://meetinglibrary.asco.org/content/95649-114 link to abstract] [http://meetinglibrary.asco.org/content/74842 link to oral abstract session]
# A. Oliver Sartor, Daniel Heinrich, Joe M. O'Sullivan, Sophie D. Fossa, Ales Chodacki, Pawel J. Wiechno, John P. Logue, Mihalj Seke, Anders Widmark, Dag Clement Johannessen, Sten Nilsson, Peter Hoskin, David Bottomley, Robert Edward Coleman, Nicholas J. Vogelzang, C. Gillies O'Bryan-Tear, Jose E. Garcia-Vargas, Minghua Shan, Chris Parker. Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). 2012 ASCO Annual Meeting Abstract 4551. [http://meetinglibrary.asco.org/content/94891-114 link to abstract]
# Nicholas J. Vogelzang, Chris Parker, Sten Nilsson, Robert Edward Coleman, C. Gillies O'Bryan-Tear, Minghua Shan, A. Oliver Sartor. Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA). 2013 ASCO Genitourinary Cancers Symposium Abstract 11. [https://meetinglibrary.asco.org/content/107117-134 link to abstract]
# Sten Nilsson, A. Oliver Sartor, Oyvind S. Bruland, Fang Fang, Anne-Kirsti Aksnes, Chris Parker. Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. 2013 ASCO Genitourinary Cancers Symposium Abstract 19. [http://meetinglibrary.asco.org/content/107297-134 link to abstract]
# '''Update:''' Nilsson S, Franz√©n L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennern√§s B, Petersson U, Johannessen DC, Sokal M, Pigott K, O'Bryan-Tear CG, Thuresson M, Bolstad B, Bruland √òS. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer. 2013 Mar;11(1):20-6. Epub 2012 Sep 26. [http://www.clinical-genitourinary-cancer.com/article/S1558-7673(12)00168-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23021204 PubMed]
-->
# '''ALSYMPCA:''' Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Foss√• SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franz√©n L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland √òS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213-23. [https://www.nejm.org/doi/full/10.1056/NEJMoa1213755 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23863050 PubMed]
## '''Subgroup analysis:''' Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Foss√• SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland √òS, Parker C. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014 Jun;15(7):738-46. Epub 2014 May 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70183-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24836273 PubMed]
## '''Subgroup analysis:''' Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014 Nov;15(12):1397-406. Epub 2014 Oct 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970474-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25439694 PubMed]
## '''HRQoL analysis:''' Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, Reuning-Scherer J, Shan M, Zhan L, Parker C. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016 May;27(5):868-74. Epub 2016 Feb 23. [https://academic.oup.com/annonc/article/27/5/868/2769826 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843190/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26912557 PubMed]

==Samarium-153 monotherapy {{#subobject:36 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:42 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/S0959-8049(97)00155-X/pdf Resche et al. 1997]
|style="background-color:#1a9851"|Phase III (E)
|Samarium-153 0.5 mCi/kg
|style="background-color:#91cf60"|Seems to have superior pain control at week 4
|-
|[http://www.goldjournal.net/article/S0090-4295%2804%2900143-8/abstract Sartor et al. 2004 (Quadramet 424Sm10/11 Study Group)]
|style="background-color:#1a9851"|Phase III (E)
|Samarium-152 (non-radioactive)
|style="background-color:#91cf60"|Seems to have superior pain control at week 4
|-
|}
====Radiotherapy====
*[[Samarium-153 (Quadramet)]] 1 mCi/kg IV over 1 minute once on day 1

====Supportive medications====
*1000 mL of fluid IV or PO given twice, 4 hours before and 6 hours after treatment

'''1 dose'''

===References===
# Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997 Sep;33(10):1583-91. [https://www.ejcancer.com/article/S0959-8049(97)00155-X/pdf link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9389919 PubMed]
# Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P; Quadramet 424Sm10/11 Study Group. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004 May;63(5):940-5. [http://www.goldjournal.net/article/S0090-4295%2804%2900143-8/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15134985 PubMed]

=Measuring disease progression=
*Criteria used for disease progression in prostate cancer clinical trials, Prostate Cancer Clinical Trials Working Group 2 (PCWG2):<ref>Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26(7):1148-59. [http://jco.ascopubs.org/content/26/7/1148.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010133/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18309951 PubMed]</ref>
**Castrate level of serum testosterone is less than 50 ng/dL (less than 1.7 nmol/L)
***However, there is controversy/disagreement in other references about whether a lower level should be used, such as less than 20 ng/dL (0.7 nmol/L)<ref>Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000 Dec 20;56(6):1021-4. [http://www.goldjournal.net/article/S0090-4295%2800%2900793-7/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11113751 PubMed]</ref>
**PSA rise
***Starting PSA of at least 2.0 ng/mL
***Rising PSA values which are measured at least 1-week apart
***Pretherapy PSA doubling times (PSA-DT) can be estimated if there are at least 3 PSA values measured at least 4 weeks apart
**Bony metastases
***At least 2 new lesions indicates progressive disease
***It is recommended to assess ambiguous results with other imaging modalities such as CT or MRI 
**Measurable lesions (RECIST) - this is a lower priority criteria by the PCWG2 because fewer patients have measurable lesions as compared to, for example, bony metastases
***Baseline imaging involves chest imaging with x-ray or CT, CT or MRI of the abdomen/pelvis, and radionuclide bone scan
***It is recommended that local disease is assessed by endorectal MRI or prostatic ultrasound
***Neurologic symptoms should be assessed with MRI of the spine and base of the skull
***Positron emission tomography (PET) is not recommended and is considered investigational
***Measurable lesions should be followed with [http://imaging.cancer.gov/clinicaltrials/imaging RECIST criteria]
***"Up to 10 visceral and nodal lesions in total should be recorded (with a maximum of five in any one organ)"
***It is suggested that a lymph node must be at least 2 cm in maximal dimension on spiral CT to count as a target lesion.

=Statistics=
*[http://jama.jamanetwork.com/article.aspx?articleid=198392 Four-Year Actuarial Progression-Free Probability (PFP) After Salvage Radiotherapy based on Gleason score, PSA, positive margins, etc.]<ref>Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM. Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy. JAMA. 2004 Mar 17;291(11):1325-32. [http://jama.jamanetwork.com/article.aspx?articleid=198392 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15026399 PubMed]</ref> (flowchart is in Figure 2)
*[http://seer.cancer.gov/statfacts/html/prost.html SEER Stat Fact Sheets: Prostate Cancer]
*[http://www.cdc.gov/CANCER/prostate/statistics/ CDC Prostate Cancer Statistics]
*[http://www.cancer.net/cancer-types/prostate-cancer/statistics Cancer.Net Prostate Cancer Statistics]

=Links=
*[http://genomedx.com/decipher-test/ Decipher], GenomeDx's genomic prognostic prostate cancer assay
**"the Decipher Test uses the expression of these biomarkers to calculate the probability of clinical metastasis within 5 years of radical prostatectomy surgery, and within 3 years of successive PSA rise (biochemical recurrence)."
*[http://www.mskcc.org/cancer-care/adult/prostate/prediction-tools MSKCC prostate cancer nomograms]
*[http://nomograms.mskcc.org/Prostate/PsaDoublingTime.aspx MSKCC PSA doubling time calculator]
*[http://nomograms.mskcc.org/Prostate/Volume.aspx MSKCC Prostate volume calculator]
*[http://prostate-cancer.oncotypedx.com/en-US/Professional.aspx Oncotype DX Prostate] Genomic Health's Genomic Prostate Score (GPS) & prognostic prostate cancer assay
*[http://urology.jhu.edu/prostate/partintables.php Partin tables] to predict pathologic stage based on clinical TNM stage, PSA, and Gleason score
*[http://www.diagnocure.com/en/products-projects/prostate-cancer/pca3-test-healthcare-practitioners.php PCA3 RNA urine test]
**[http://www.pca3.org/ PCA3.org]
*[http://www.prolaris.com/ Prolaris], Myriad's biomarker prognostic prostate cancer assay
*[https://www.roswellpark.org/apps/prostate_cancer_estimator/ Roswell Park's Calculator for Estimating Overall Life Expectancy and Lifetime Risk for Prostate Cancer Death in Newly Diagnosed Men Managed without Definitive Local Therapy]
*[http://urology.ucsf.edu/research/cancer/prostate-cancer-risk-assessment-and-the-ucsf-capra-score UCSF-CAPRA score]

=Quality of life assessment tools=
*[http://www.bidmc.org/~/media/Files/Centers%20and%20Departments/CancerCenter/prostateCancer/EPIC%20CP.pdf EPIC-CP: Expanded Prostate Cancer Index Composite for Clinical Practice] ([http://www.bidmc.org/epic twice per dayMC])
*[http://www.oregonurology.com/pdfs/aua-symptom-score.pdf AUA Symptom Score (OR)] [[Media:AUA-Symptom-Score_OR.pdf|(local backup)]]; [http://www.purclinic.com/wp-content/uploads/2014/05/AUA-Symptom-Score.pdf AUA Symptom Score (UCF)] [[Media:AUA-Symptom-Score.pdf|(local backup)]]. Also known as International Prostate Symptom Score (I-PSS/IPSS) or AUASS

=References=
<references/>

[[Category:Prostate cancer regimens]]
[[Category:Disease-specific pages]]
[[Category:Genitourinary cancers]]
